279 results found.

Diabetes, or Diabetes Mellitus, Type 2 Clinical Trial using insulin degludec; insulin glargine

Novo Nordisk - Recruiting 18 years or older.
- A Randomised, Double Blind, Cross-over Trial Comparing the Safety and Efficacy of Insulin Degludec and Insulin Glargine, With or Without OADs in Subjects With Type 2 Diabetes (SWITCH 2).
insulin degludec; insulin glargine

Type 2 Diabetes Clinical Trial using Insulin glargine/lixisenatide HOE901/AVE0010; Insulin glargine HOE901; Metformin

Sanofi - Recruiting 18 years or older.
- A Randomized, 30-week, Active-controlled, Open Label, 2- Treatment Arm, Parallel-group, Multicenter Study Comparing the Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination to Insulin Glargine With or Without Metformin in Patients With T2DM.
Insulin glargine/lixisenatide HOE901/AVE0010; Insulin glargine HOE901; Metformin

Type 2 Diabetes Clinical Trial using MK-3102; Sitagliptin; Placebo to MK-3102; Placebo to Sitagliptin; Open-label Metformin; Open-label Glimepiride

Merck Sharp & Dohme Corp. - Recruiting 18 years or older.
- A Phase III, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Sitagliptin in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin.
MK-3102; Sitagliptin; Placebo to MK-3102; Placebo to Sitagliptin; Open-label Metformin; Open-label Glimepiride

Type 2 Diabetes Mellitus Clinical Trial using MK-3102; Placebo

Merck Sharp & Dohme Corp. - Recruiting 40 years or older.
- A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess Cardiovascular Outcomes Following Treatment With MK-3102 in Subjects With Type 2 Diabetes Mellitus.
MK-3102; Placebo

Diabetes, or Diabetes Mellitus, Type 2 Clinical Trial using insulin degludec; insulin glargine

Novo Nordisk - Recruiting 50 years or older.
- A Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Subjects With Type 2 Diabetes at High Risk of Cardiovascular Events.
insulin degludec; insulin glargine

Diabetes Mellitus, Type 2 Clinical Trial using Trazenta

Boehringer Ingelheim - Recruiting N/A or older.
- Post Marketing Surveillance on Long Term Drug Use of Trazentar Tablets as add-on Therapy in Patients With Type 2 Diabetes Mellitus.
Trazenta

Type 2 Diabetes Mellitus Clinical Trial using Exenatide Once Weekly; Placebo

Bristol-Myers Squibb - Recruiting 18 years or older.
- Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL). A Randomized, Placebo Controlled Clinical Trial to Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly in Patients With Type 2 Diabetes Mellitus..
Exenatide Once Weekly; Placebo

Diabetes Mellitus, Type 2 Clinical Trial using Canagliflozin 100 mg; Canagliflozin 50 mg; Canagliflozin 300 mg; Placebo

Janssen Research & Development, LLC - Recruiting 10 years to 17 years.
- Open-Label, Multicenter, Multiple Oral Dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents ò10 to <18 Years of Age With Type 2 Diabetes Mellitus and Currently on a Stable Dose of Metformin.
Canagliflozin 100 mg; Canagliflozin 50 mg; Canagliflozin 300 mg; Placebo

Type 2 Diabetes Mellitus Clinical Trial using MK-3102; Matching placebo to MK-3012; Glimepiride; Metformin

Merck Sharp & Dohme Corp. - Recruiting 18 years or older.
- A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial to Study the Safety and Efficacy of the Addition of MK-3102 to Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Combination Therapy With Glimepiride and Metformin.
MK-3102; Matching placebo to MK-3012; Glimepiride; Metformin

Type 2 Diabetes Mellitus Clinical Trial using Ertugliflozin (5 mg); Ertugliflozin (10 mg); Placebo to Ertuglifozin; Metformin; Placebo to Metformin

Merck Sharp & Dohme Corp. - Recruiting 18 years or older.
- A Phase 3, Randomized, Double-blind, Placebo-controlled, 26-week Multicenter Study With a 26-Week Extension to Evaluate the Efficacy and Safety of Ertugliflozin Monotherapy in the Treatment of Subjects With Type 2 Diabetes Mellitus and Inadequate Glycemic Control Despite Diet and Exercise.
Ertugliflozin (5 mg); Ertugliflozin (10 mg); Placebo to Ertuglifozin; Metformin; Placebo to Metformin

Type 2 Diabetes Mellitus Clinical Trial using MK-3102; Placebo to MK-3102; Glipizide; Placebo to glipizide; Insulin

Merck Sharp & Dohme Corp. - Recruiting 30 years or older.
- A Phase III, Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy and Safety of MK-3102 Versus Placebo in Subjects With Type 2 Diabetes Mellitus With Moderate or Severe Chronic Kidney Disease or Kidney Failure on Dialysis Who Have Inadequate Glycemic Control.
MK-3102; Placebo to MK-3102; Glipizide; Placebo to glipizide; Insulin

Diabetes Mellitus, Type 2 Clinical Trial using Metformin; Sitagliptin / Metformin; Placebo to Metformin; Placebo to Sitagliptin / Metformin

Merck Sharp & Dohme Corp. - Recruiting 10 years to 17 years.
- A Phase III, Multicenter, Double-Blind, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-0431A (A Fixed-Dose Combination Tablet of Sitagliptin and Metformin) in Pediatric Patients With Type 2 Diabetes Mellitus.
Metformin; Sitagliptin / Metformin; Placebo to Metformin; Placebo to Sitagliptin / Metformin

Type 2 Diabetes Mellitus Clinical Trial using MK-0431A XR; Placebo to MK-0431A XR; Metformin XR; Placebo to metformin XR; Insulin glargine

Merck Sharp & Dohme Corp. - Recruiting 10 years to 17 years.
- A Phase III Multicenter, Double-blind, Randomized, Placebo-controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-0431A XR (a Fixed-dose Combination Tablet of Sitagliptin and Extended-release Metformin) in Pediatric Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy.
MK-0431A XR; Placebo to MK-0431A XR; Metformin XR; Placebo to metformin XR; Insulin glargine

Type 2 Diabetes Clinical Trial using Paricalcitol; placebo

Mario Negri Institute for Pharmacological Research - Recruiting 18 years to 80 years.
- A Prospective, Randomized, Cross-over, Double-blind, Placebo-controlled Study to Assess the Antiproteinuric Effect of Selective Vitamin d Receptor Activation by Paricalcitol in Type 2 Diabetes Patients on Low or High Sodium Diet and Stable Ras Inhibitor Therapy.
Paricalcitol; placebo

Type 2 Diabetes, or Obesity Clinical Trial using Calorie restriction (25%); Ad libitum health diet

Mario Negri Institute for Pharmacological Research - Recruiting 40 years or older.
- LONG-TERM EFFECTS OF CALORIC RESTRICTION ON METABOLIC, RENAL AND RETINAL HEALTH IN SUBJECTS AFFECTED BY OBESITY AND TYPE 2 DIABETES.
Calorie restriction (25%); Ad libitum health diet

Phone Cognitive Behavioral Therapy, or Smartphone App Clinical Trial using CBT; Smartphone app; Standard Diabetes Care at PCP

University of Pittsburgh - Recruiting 30 years to 65 years.
- mHealth Skill Enhancement Plus Phone CBT for Type 2 Diabetes Distress Medication Nonadherence: Pilot Study.
CBT; Smartphone app; Standard Diabetes Care at PCP

Diabetes Mellitus, Type 2 Clinical Trial using Linagliptin; Empagliflozin + Linagliptin; Empaglifozin placebo + Linagliptin placebo

Boehringer Ingelheim - Recruiting 18 years or older.
- A Phase III, Randomised, Double-blind, Parallel Group, 24 Week Study to Evaluate Efficacy and Safety of Once Daily Empagliflozin 10 mg and 25 mg Compared to Placebo, All Administered as Oral Fixed Dose Combinations With Linagliptin 5 mg, in Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control After 16 Weeks Treatment With Linagliptin 5 mg Once Daily on Metformin Background Therapy..
Linagliptin; Empagliflozin + Linagliptin; Empaglifozin placebo + Linagliptin placebo

Diabetes Mellitus, Type 2 Clinical Trial using Trajenta duo

Boehringer Ingelheim - Recruiting 18 years or older.
- A Regulatory Requirement Non Interventional Study to Monitor the Safety and Effectiveness of Trajenta Duo® (Linagliptin/Metformin HCl, 2.5 mg/500 mg, 2.5 mg/850 mg and 2.5 mg/1000 mg, b.i.d) in Korean Patients With Type 2 Diabetes Mellitus.
Trajenta duo

Diabetes Mellitus, Type 2 Clinical Trial using Trajenta tablet

Boehringer Ingelheim - Recruiting 19 years or older.
- A Regulatory Requirement Non Interventional Study to Monitor the Safety and Effectiveness of Trajenta (Linagliptin, 5 mg, q.d) in Korean Patients With Type 2 Diabetes Mellitus(SELINA Study).
Trajenta tablet

Diabetes Mellitus, Type 2, or Healthy Clinical Trial using Empagliflozin; BI 10773

Boehringer Ingelheim - Recruiting 18 years to 70 years.
- An Open-label Mechanistic Study to Examine the Effect of Oral Empagliflozin (25 mg q.d.) on Kinetics of Renal Glucose Reabsorption in Patients With Type 2 Diabetes Mellitus and Healthy Controls.
Empagliflozin; BI 10773

Diabetes Mellitus, Type 1 Clinical Trial using Empagliflozin medium placebo; Empagliflozin low placebo; Empagliflozin high placebo; Empagliflozin medium; Empagliflozin low; Empagliflozin high

Boehringer Ingelheim - Recruiting 18 years to 65 years.
- A 28-day Randomised, Placebo-controlled, Double-blind Parallel Group Phase IIa Trial to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Once Daily Oral Doses of 2.5 mg, 10 mg, and 25 mg Empagliflozin as Adjunctive to Insulin in Patients With Type 1 Diabetes Mellitus (EASE-2).
Empagliflozin medium placebo; Empagliflozin low placebo; Empagliflozin high placebo; Empagliflozin medium; Empagliflozin low; Empagliflozin high

Diabetes Mellitus, Type 2 Clinical Trial using Placebo; Linagliptin 5mg

Boehringer Ingelheim - Recruiting 18 years to 80 years.
- A Phase IIIb, Multicenter, Multinational, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Evaluate the Glycemic and Renal Efficacy of Once Daily Administration of Linagliptin 5 mg for 24 Weeks in Type 2 Diabetes Patients, With Micro- or Macroalbuminuria (30-3000mg/g Creatinine) on Top of Current Treatment With Angiotensin ConvEnzyme Inhibitor or Angiotensin Receptor Blocker - MARLINA (Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin).
Placebo; Linagliptin 5mg

Diabetes Mellitus, Type 2 Clinical Trial using OAD; Trazenta

Boehringer Ingelheim - Recruiting N/A or older.
- Post Marketing Surveillance on Long Term Drug Use of Trazenta® Tablets in Patients With Type 2 Diabetes Mellitus.
OAD; Trazenta

Diabetes Mellitus, Type 2 Clinical Trial using BI 10773; BI 10773 Placebo; BI 10773 / BI 1356; BI 10773 / BI 1356 Placebo

Boehringer Ingelheim - Recruiting 18 years or older.
- A Phase III, Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Linagliptin 5 mg Compared to Placebo, Administered as Oral Fixed Dose Combination With Empagliflozin 10 mg or 25 mg for 24 Weeks, in Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control After 16 Weeks of Treatment With Empagliflozin 10 mg or 25 mg on Metformin Background Therapy.
BI 10773; BI 10773 Placebo; BI 10773 / BI 1356; BI 10773 / BI 1356 Placebo

Autoantibody Positive, Non-diabetic Relatives at Risk for Type 1 Clinical Trial using Teplizumab

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) - Recruiting 8 years to 45 years.
- AntiCD3 Mab (Teplizumab) For Prevention of Diabetes In Relatives At-Risk for Type 1 Diabetes Mellitus.
Teplizumab

Diabetes Mellitus, Type 2 Clinical Trial using Placebo; Linagliptin

Boehringer Ingelheim - Recruiting 18 years or older.
- CARMELINA: A Multicenter, International, Randomized, Parallel Group, Double-blind, Placebo-controlled, Cardiovascular Safety and Renal Microvascular Outcome Study With Linagliptin, 5 mg Once Daily in Patients With Type 2 Diabetes Mellitus at High Vascular Risk.
Placebo; Linagliptin

Diabetes Mellitus, Type 2, or Hyperglycemia Clinical Trial using Empagliflozin low dose qd; Metformin 500 mg bid; Metformin 1000 mg bid; Empagliflozin high dose qd; Empagliflozin low dose bid; Empagliflozin high dose bid

Boehringer Ingelheim - Recruiting 18 years or older.
- A 24-week Phase III Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Twice Daily Oral Administration of Empagliflozin + Metformin Compared With the Individual Components of Empagliflozin or Metformin in Drug Naive Patients With Type 2 Diabetes Mellitus.
Empagliflozin low dose qd; Metformin 500 mg bid; Metformin 1000 mg bid; Empagliflozin high dose qd; Empagliflozin low dose bid; Empagliflozin high dose bid

Diabetes Mellitus, Type 2 Clinical Trial using placebo; BI1356 low dose; BI1356 high dose

Boehringer Ingelheim - Recruiting 10 years to 17 years.
- A Randomised, Double-blind, Placebo-controlled, Parallel Group Dose-finding Study of Linagliptin (1 and 5 mg Administered Orally Once Daily) Over 12 Weeks in Children and Adolescents, From 10 to 17 Years of Age, With Type 2 Diabetes Mellitus.
placebo; BI1356 low dose; BI1356 high dose

Type 1 Diabetes Mellitus Clinical Trial using Secukinumab; Placebo

Novartis - Recruiting 8 years to 35 years.
- A Randomized, Double-blind, Multiple Dose, Placebo-controlled Study to Evaluate the Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Efficacy of Secukinumab in Adult and Pediatric Patients With New-onset Type 1 Diabetes Mellitus (T1D).
Secukinumab; Placebo

Exocrine Pancreatic Insufficiency in Subjects With Diabetes Melli Clinical Trial using Creon; Creon 25000 matching Placebo

Abbott - Recruiting 30 years or older.
- A Double-blind, Randomized, Multi-center, Placebo-controlled, Parallel-group Study to Assess the Effect of Creonr on Pancreatic Exocrine Insufficiency in Subjects With Diabetes Mellitus Type 2.
Creon; Creon 25000 matching Placebo

Brief CBT, or Smart-phone App Clinical Trial using Brief CBT

University of Pittsburgh - Recruiting 30 years to 65 years.
- Brief CBT Interventions Delivered by Nurse Care Managers to Improve Type 2 Diabetes Outcomes: Pilot Study.
Brief CBT

Type 2 Diabetes Clinical Trial using HM11260C; Placebo

Hanmi Pharmaceutical Company Limited - Recruiting 18 years to 74 years.
- A Phase II, 16-week, Double-blind, Placebo-controlled, Parallel-group, Randomised, Multicentre Trial to Assess Effect on Glycaemic Control of Three Doses of HM11260C in Subjects With Inadequately Controlled Type 2 Diabetes Receiving a Stable Dose of Metformin.
HM11260C; Placebo

Type 2 Diabetes in Obese Subjects Clinical Trial using EndoBarrier; Sham Procedure

GI Dynamics - Recruiting 21 years to 65 years.
- A Randomized, Multi-Center, Pivotal Efficacy and Safety Study Comparing the EndoBarrier Gastrointestinal Liner System vs. Sham for Glycemic Improvement in Inadequately Controlled Obese Type 2 Diabetic Subjects on Oral Anti-Diabetes Agents.
EndoBarrier; Sham Procedure

Diabetes, or Diabetes Mellitus, Type 1 Clinical Trial using insulin degludec; insulin glargine; insulin aspart

Novo Nordisk - Recruiting 18 years or older.
- A Randomised, Double Blind, Cross-over Trial Comparing the Safety and Efficacy of Insulin Degludec and Insulin Glargine, Both With Insulin Aspart as Mealtime Insulin in Subjects With Type 1 Diabetes (BEGIN™: Switch 1).
insulin degludec; insulin glargine; insulin aspart

Type 2 Diabetes Clinical Trial using DIAMOND System

Metacure - Recruiting 18 years to 70 years.
- The DIAMOND® for the Treatment of Type 2 Diabetes: Can Blood Triglycerides Level be the Predictor for Therapy Efficiency A Multicentre, Prospective, Semi-randomized Study.
DIAMOND System

Essential Hypertension Complicated by Type 2 Diabetes Mellitus Clinical Trial using Azilsartan; Telmisartan

Takeda - Recruiting 20 years or older.
- A Study to Explore the Effects of Azilsartan Compared to Telmisartan on Insulin Resistance of Patients With Essential Hypertension on Type 2 Diabetes Mellitus by HOMA-R.
Azilsartan; Telmisartan

Hypoglycemia Clinical Trial using G-Pen Mini™ (glucagon injection)

Xeris Pharmaceuticals - Recruiting 18 years to 30 years.
- A Randomized, Phase 2a, Blinded, 3-Way Crossover Dose-Ranging Study With G-Pen Mini™ (Glucagon Injection) to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Patients With Type 1 Diabetes Mellitus (T1DM).
G-Pen Mini™ (glucagon injection)

Diabetes, or Diabetes Mellitus, Type 1 Clinical Trial using liraglutide; placebo

Novo Nordisk - Recruiting 18 years to 75 years.
- The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes. A 52-week Randomised, Treat-to-target, Placebo-controlled, Double Blinded, Parallel Group, Multinational, Multi-centre Trial.
liraglutide; placebo

Diabetes, or Diabetes Mellitus, Type 2 Clinical Trial using semaglutide; exenatide

Novo Nordisk - Recruiting 18 years or older.
- Efficacy and Safety of Semaglutide Once-weekly Versus Exenatide ER 2.0 mg Once-weekly as add-on to 1-2 Oral Antidiabetic Drugs (OADs) in Subjects With Type 2 Diabetes (SUSTAINT 3 - vs. QW GLP-1).
semaglutide; exenatide

Type 2 Diabetes Mellitus Clinical Trial using DIAMOND System

Metacure - Recruiting 21 years to 70 years.
- An Advanced Configuration (The Third Generation) of the DIAMOND System for the Treatment of T2DM Patients - A Randomized, Double Blind Study.
DIAMOND System

Type 1 Diabetes, or Type 2 Diabetes Clinical Trial using No treatment

Abbott Diabetes Care - Recruiting 18 years or older.
- Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System.
No treatment

Diabetes, Gestational, or Diabetes, Type 2 Clinical Trial using Insulin

St. Luke's-Roosevelt Hospital Center - Recruiting 18 years or older.
- Insulin Detemir Versus Insulin NPH: A Randomized Prospective Study Comparing Glycemic Control in Pregnant Women With Diabetes.
Insulin

Type 2 Diabetes Mellitus, or Cardiovascular Disease Clinical Trial using Liraglutide; Sitagliptin

University of Leicester - Recruiting 18 years to 50 years.
- Impact of Liraglutide on Cardiac Function and Structure in Young Adults With Type 2 Diabetes: an Open-label, Randomised Active-comparator Trial.
Liraglutide; Sitagliptin

Diabetes Mellitus, Type 2, or Albuminuria Clinical Trial using Placebo; Canagliflozin, 100 mg; Canagliflozin, 300 mg

Janssen Research & Development, LLC - Recruiting 30 years or older.
- A Randomized, Multicenter, Double-Blind, Parallel, Placebo-Controlled Study of the Effects of Canagliflozin on Renal Endpoints in Adult Subjects With Type 2 Diabetes Mellitus.
Placebo; Canagliflozin, 100 mg; Canagliflozin, 300 mg

Type 1 Diabetes Clinical Trial using contingency management

University of Connecticut Health Center - Recruiting 15 years to 21 years.
- A Pilot Study Examining a Reinforcement Approach to Improve Diabetes Management.
contingency management

Diabetes Mellitus, Type 1 Clinical Trial using dietary intervention

Helsinki University - Recruiting N/A to 12 Months.
- Early Dietary Intervention and Later Signs of Beta-Cell Autoimmunity: Potential Mechanisms.
dietary intervention

Heart Failure Clinical Trial using BAY94-8862; Eplerenone; Placebo

Bayer - Recruiting 18 years or older.
- A Randomized, Double-blind, Double-dummy, Multi-center Study to Assess Safety and Efficacy of BAY94-8862 in Japanese Subjects With Emergency Presentation at the Hospital Because of Worsening Chronic Heart Failure With Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Moderate Chronic Kidney Disease Alone Versus Eplerenone.
BAY94-8862; Eplerenone; Placebo

Type 2 Diabetes Mellitus Clinical Trial using Ertugliflozin 5 mg; Ertugliflozin 15 mg; Placebo to Ertugliflozin; Glimepiride; Placebo to Glimepiride; Basal Insulin; Metformin

Merck Sharp & Dohme Corp. - Recruiting 18 years or older.
- A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 26-Week Multicenter Study With a 78-Week Extension To Evaluate The Efficacy And Safety Of Ertugliflozin In Subjects With Type 2 Diabetes Mellitus And Inadequate Glycemic Control On Metformin Monotherapy.
Ertugliflozin 5 mg; Ertugliflozin 15 mg; Placebo to Ertugliflozin; Glimepiride; Placebo to Glimepiride; Basal Insulin; Metformin

Diabetes Mellitus, Type 2 Clinical Trial using Ticagrelor 90 mg; Ticagrelor placebo

AstraZeneca - Recruiting 50 years or older.
- A Multinational, Randomised, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Ticagrelor 90 mg Twice Daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Stroke in Patients With Type 2 Diabetes Mellitus (THEMIS - Effect of Ticagrelor on Health Outcomes in diabEtes Mellitus Patients Intervention Study).
Ticagrelor 90 mg; Ticagrelor placebo

Diabetes Mellitus, or Obesity Clinical Trial using Oral glucose tolerance test

National Institutes of Health Clinical Center (CC) - Recruiting 19 years to 65 years.
- Inhibition of Intestinal Glucose Absorption by the Bioflavonoid Quercetin in the Obese and in Obese Type 2 Diabetics.
Oral glucose tolerance test

Morbid Obesity, Diabetes Mellitus Type 2, Insulin Resistance, Obs Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- Study of the Phenotype of Overweight and Obese Adults.

Diabetes, or Diabetes Mellitus, Type 2 Clinical Trial using insulin aspart (FIAsp); insulin aspart; insulin glargine

Novo Nordisk - Recruiting 18 years or older.
- Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes.
insulin aspart (FIAsp); insulin aspart; insulin glargine

Type 1 Diabetes, Type 2 Diabetes, Immunologically Mediated Type 1 Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 2 years or older.
- Natural History of Autoimmune Diabetes and Its Complications.

Type 1 Diabetes, or Hypoglycemia Unawareness Clinical Trial using Naltrexone

University of Minnesota - Clinical and Translational Science Institute - Recruiting 18 years to 65 years.
- Study of the Effect of Naltrexone on Cerebral Blood Flow and Hypoglycemia in Type 1 Diabetes Mellitus.
Naltrexone

Type 1 Diabetes, or Hypoglycemia Unawareness Clinical Trial using somatostatin

University of Minnesota - Clinical and Translational Science Institute - Recruiting 18 years to 65 years.
- Measurement of Glucose Metabolism in Humans Using Magnetic Resonance at 4 Tesla. Substudy: Hypoglycemia Unawareness.
somatostatin

Obesity, Diet Therapy, or Diabetes Type 2 Clinical Trial using Controlling Gestational Weight Gain

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- Lifestyle Interventions for Expectant Moms (LIFE-Moms Phoenix)-Phoenix.
Controlling Gestational Weight Gain

Prediabetes, or Type 2 Diabetes Clinical Trial using Vitamin D (Cholecalciferol); Placebo

Tufts Medical Center - Recruiting 30 years or older.
- Vitamin D and Type 2 Diabetes Study.
Vitamin D (Cholecalciferol); Placebo

Diabetes Mellitus, Type 1 Clinical Trial

Yale University - Recruiting 10 years to 37 years.
- ITN0127AI Autoimmunity-blocking Antibody for Tolerance in Recently Diagnosed Type 1 Diabetes (AbATE) Follow-Up Study.

Type 2 Diabetes Clinical Trial using lixisenatide (AVE0010); placebo

Sanofi - Recruiting 70 years or older.
- A Randomized, Double-blind, Placebo-controlled, 2-arm Parallel-group, Multicenter, 24 Week Study Assessing the Safety and Efficacy of Lixisenatide in Older Patients With Type 2 Diabetes Inadequately Controlled on Their Current Diabetes Treatment Regimen.
lixisenatide (AVE0010); placebo

Type 2 Diabetes Mellitus Clinical Trial using Lixisenatide (AVE0010); Placebo

Sanofi - Recruiting 10 years to 65 years.
- A Randomized, Double-blind, Placebo Controlled Trial to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Lixisenatide in Paediatric (10 - 17 Years Old) and Adult Patients With Type 2 Diabetes.
Lixisenatide (AVE0010); Placebo

Type 2 Diabetes Mellitus Clinical Trial using lixisenatide AVE0010

Sanofi - Recruiting 20 years or older.
- An Open-label, Multicenter 24-Week And 52-Week Study Assessing The Safety And Tolerability Of Lixisenatide In Monotherapy In Patients With Type 2 Diabetes.
lixisenatide AVE0010

Type 2 Diabetes Mellitus Clinical Trial using Lixisenatide (AVE0010); Placebo

Sanofi - Recruiting 18 years or older.
- A Randomized, Double-blind, Placebo-controlled, 2-arm Parallel-group, Multicenter Study With a 24-week Treatment Period Assessing the Efficacy and Safety of Lixisenatide in Patients With Type 2 Diabetes Insufficiently Controlled With Basal Insulin With or Without Metformin.
Lixisenatide (AVE0010); Placebo

Type 2 Diabetes Clinical Trial using Insulin glargine/lixisenatide HOE901/AVE0010; Insulin glargine HOE901; Lixisenatide AVE0010; Metformin

Sanofi - Recruiting 18 years or older.
- A Randomized, 30 Week, Active-controlled, Open-label, 3-treatment Arm, Parallel-group Multicenter Study Comparing the Efficacy and Safety of Insulin Glargine/ Lixisenatide Fixed Ratio Combination to Insulin Glargine Alone and to Lixisenatide Alone on Top of Metformin in Patients With Type 2 Diabetes Mellitus T2DM.
Insulin glargine/lixisenatide HOE901/AVE0010; Insulin glargine HOE901; Lixisenatide AVE0010; Metformin

Diabetes, or Diabetes Mellitus, Type 2 Clinical Trial using semaglutide; oral placebo

Novo Nordisk - Recruiting 18 years or older.
- Multiple Dose Trial Examining Dose Range, Escalation and Efficacy of Oral Semaglutide in Subjects With Type 2 Diabetes.
semaglutide; oral placebo

Type 2 Diabetes Clinical Trial using lixisenatide (AVE0010); insulin glulisine (HMR1964)

Sanofi - Recruiting 18 years or older.
- A Randomized, Open-label, Active-controlled, 3-arm Parallel-group, 26-week Study Comparing the Efficacy and Safety of Lixisenatide to That of Insulin Glulisine Once Daily and Insulin Glulisine Three Times Daily in Patients With Type 2 Diabetes Insufficiently Controlled With Insulin Glargine With or Without Metformin.
lixisenatide (AVE0010); insulin glulisine (HMR1964)

Type 2 Diabetes Clinical Trial using Liraglutide; diet; Aspirin

Royal Devon and Exeter NHS Foundation Trust - Recruiting 18 years to 70 years.
- Does Glucagon-like Polypeptide 1 Improve Vascular Function and Inflammation?.
Liraglutide; diet; Aspirin

Type 2 Diabetes, or Obesity Clinical Trial using GLP-1; Placebo

Royal Devon and Exeter NHS Foundation Trust - Recruiting 18 years or older.
- The Microvascular Function of GLP-1 and Its Analogues in Humans, in Vivo: the Role of DPP-IV Inhibition.
GLP-1; Placebo

Diabetes Mellitus Type 2, or Hypertension Clinical Trial using Ginseng; Wheat Bran

St. Michael's Hospital, Toronto - Recruiting 40 years to 75 years.
- Efficacy and Safety of Combined Rg3-enriched Korean Red Ginseng (Panax Ginseng C.A. Meyer) and American Ginseng (Panax Quinquefolius) as Poly-therapy in the Management of Concomitant Hypertension in Type 2 Diabetes.
Ginseng; Wheat Bran

Diabetes, or Diabetes Mellitus, Type 1 Clinical Trial using insulin degludec/insulin aspart; insulin aspart; insulin detemir

Novo Nordisk - Recruiting 1 year to 17 years.
- A Trial Investigating the Efficacy and Safety of Insulin Degludec/Insulin Aspart Once Daily Plus Insulin Aspart for the Remaining Meals Versus Insulin Detemir Once or Twice Daily Plus Meal Time Insulin Aspart in Children and Adolescents With Type 1 Diabetes Mellitus.
insulin degludec/insulin aspart; insulin aspart; insulin detemir

Diabetes Mellitus, Type 2 Clinical Trial using PF-06291874; Placebo

Pfizer - Recruiting 18 years to 70 years.
- A Phase 1, Placebo-Controlled Trial To Assess The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Multiple Escalating Oral Doses Of PF-06291874 In Adults With Type 2 Diabetes Mellitus.
PF-06291874; Placebo

Type 2 Diabetes Mellitus, or Obesity Clinical Trial using 13C inulin; Inulin; Placebo

Maastricht University Medical Center - Recruiting 20 years to 50 years.
- SCFA Production and Their Metabolic Effects After Inulin Ingestion.
13C inulin; Inulin; Placebo

Obesity, Morbid, or Diabetes Mellitus Type 2 Clinical Trial

Merck Sharp & Dohme Corp. - Recruiting 20 years to 60 years.
- Gut Hormone Profiling in Peripheral Blood After Bariatric Surgery in Obese Patients With Type 2 Diabetes.

Long-standing Type 1 Diabetes Mellitus Clinical Trial using Beta-Air device for encapsulation of transplanted human islets

Uppsala University Hospital - Recruiting 18 years or older.
- An Open Label, Pilot Investigation, to Assess the Safety and Efficacy of Transplantation of Macro-encapsulated Human Islets Within the Bioartificial Pancreas Beta-Air in Patients With Type 1 Diabetes Mellitus.
Beta-Air device for encapsulation of transplanted human islets

Diabetes Type 1, or Endothelial Dysfunction Clinical Trial using Single pancreas transplantation

Oslo University Hospital - Recruiting 18 years or older.
- Assessment of Cardiovascular Risk Factors, Including Endothelial Function, After Restoration of Normoglycemia Following Single Pancreas Transplantation.
Single pancreas transplantation

Type 2 Diabetes Mellitus Clinical Trial using Telemedical coaching; Telemedicine

West German Center of Diabetes and Health - Recruiting 25 years to 79 years.
- Diabetes Coaching Study.
Telemedical coaching; Telemedicine

Diabetic Nephropathies Clinical Trial using BAY94-8862; Placebo

Bayer - Recruiting 18 years or older.
- A Randomized, Double-blind, Placebo-controlled, Multi-center Study to Assess the Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy.
BAY94-8862; Placebo

Diabetic Nephropathies Clinical Trial using BAY94-8862; Placebo; BAY 94-8862

Bayer - Recruiting 18 years or older.
- A Randomized, Double-blind, Placebo-controlled, Multi-center Study to Assess the Safety and Efficacy of Different Oral Doses of BAY94-8862 in Japanese Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy.
BAY94-8862; Placebo; BAY 94-8862

Diabetes Mellitus, Type 2 Clinical Trial using Web-based insulin titration

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) - Recruiting 18 years to 80 years.
- Web-based Insulin Titration: Improving Diabetes Care in the Netherlands. An Efficacy Study..
Web-based insulin titration

Type 2 Diabetes Mellitus Clinical Trial using MK-3102; Glimepiride; MK-3102 Placebo; Glimepiride Placebo

Merck Sharp & Dohme Corp. - Recruiting 18 years or older.
- A Phase III, Multicenter, Double-Blind, Randomized Trial to Evaluate the Safety and Efficacy of MK-3102 Compared With Glimepiride in Subjects With Type 2 Diabetes Mellitus For Whom Metformin is Inappropriate Due to Intolerance or Contraindication.
MK-3102; Glimepiride; MK-3102 Placebo; Glimepiride Placebo

Diabetes, or Diabetes Mellitus, Type 2 Clinical Trial using semaglutide; placebo

Novo Nordisk - Recruiting 18 years or older.
- Efficacy and Safety of Semaglutide Once-weekly Versus Placebo in Drug-na‹ve Subjects With Type 2 Diabetes.
semaglutide; placebo

Type 2 Diabetes Mellitus Clinical Trial using Ertugliflozin; Placebo

Merck Sharp & Dohme Corp. - Recruiting 40 years or older.
- Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess Cardiovascular Outcomes Following Treatment With Ertugliflozin (MK-8835/PF-04971729) in Subjects With Type 2 Diabetes Mellitus and Established Vascular Disease.
Ertugliflozin; Placebo

Diabetes Mellitus, Type 2 Clinical Trial using PF-05175157; Placebo

Pfizer - Recruiting 18 years to 65 years.
- A 6-Week Phase 2a Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study To Assess Safety, Tolerability And Pharmacodynamics Of Oral PF-05175157 As Monotherapy In Subjects With Type 2 Diabetes Mellitus.
PF-05175157; Placebo

Type 2 Diabetes Mellitus Clinical Trial using Ertugliflozin; Placebo

Merck Sharp & Dohme Corp. - Recruiting 25 years or older.
- A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Ertugliflozin (MK-8835/PF-04971729) in Subjects With Type 2 Diabetes Mellitus With Stage 3 Chronic Kidney Disease Who Have Inadequate Glycemic Control on Background Antihyperglycemic Therapy.
Ertugliflozin; Placebo

Diabetes Mellitus Clinical Trial using MK-3102; Placebo to MK-3102; Metformin

Merck Sharp & Dohme Corp. - Recruiting 18 years to 44 years.
- A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of MK-3102 in ò18 and <45 Year-Old Subjects With Type 2 Diabetes Mellitus and Inadequate Glycemic Control.
MK-3102; Placebo to MK-3102; Metformin

Type 2 Diabetes Mellitus Clinical Trial using Ertugliflozin; Glimepiride; Placebo to Ertugliflozin; Placebo to Glimepiride; Metformin; Sitagliptin

Merck Sharp & Dohme Corp. - Recruiting 18 years or older.
- A Phase III, Multicenter, Randomized, Double-Blind, Active-Comparator-Controlled Clinical Trial to Study the Safety and Efficacy of the Addition of Ertugliflozin (MK-8835/PF-04971729) Compared With the Addition of Glimepiride in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin.
Ertugliflozin; Glimepiride; Placebo to Ertugliflozin; Placebo to Glimepiride; Metformin; Sitagliptin

Obesity, Insulin Resistance, Overweight, or Diabetes Mellitus, Ty Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 8 years to 25 years.
- Natural History of Type 2 Diabetes Mellitus in Children and Young Adults.

Type 2 Diabetes Mellitus Clinical Trial using Sitagliptin/metformin XR; Placebo

Merck Sharp & Dohme Corp. - Recruiting 10 years to 17 years.
- A Study to Assess the Pharmacokinetics and the Ability for Pediatric Patients With Type 2 Diabetes to Swallow MK-0431A XR Tablets.
Sitagliptin/metformin XR; Placebo

Diabetes Mellitus, Type 1 Clinical Trial using LY2605541; Insulin Glargine

Eli Lilly and Company - Recruiting 18 years to 65 years.
- Assessment of the Effects of LY2605541 on Triglyceride Metabolism, Compared to Insulin Glargine, in Patients With Type 1 Diabetes Mellitus.
LY2605541; Insulin Glargine

Diabetes Mellitus, Type 2, or Obesity Clinical Trial using Sport; Tocilizumab; Sitagliptin

University of Zurich - Recruiting 18 years to 75 years.
- A Lifestyle Intervention Study Investigating the Role of Interleukin-6 in the Beneficial Effect of Exercise on Beta-cell Function in Obese People and Patients With Type 2 Diabetes.
Sport; Tocilizumab; Sitagliptin

Diabetes Mellitus Type 2 Clinical Trial

GWT-TUD GmbH - Recruiting 18 years or older.
- Evaluation of the Impact of the CONTOURr USB Blood Glucose Monitoring System With Integrated Data Management on Glycaemic Control in Insulin-treated Diabetic Patients.

Type 2 Diabetes Mellitus, or Periodontal Disease Clinical Trial using non-surgical periodontal treatment; Supragingival biofilm control

University of Sao Paulo - Recruiting 30 years to 80 years.
- .
non-surgical periodontal treatment; Supragingival biofilm control

Insulin Resistance, Type 2 Diabetes Mellitus, Obesity, Androgen D Clinical Trial using Acyline; Testosterone 1.62% gel; Letrozole; Placebo gel (for Testosterone 1.62% gel); Placebo pill (for Letrozole)

University of Washington - Recruiting 25 years to 55 years.
- Androgen-mediated Pathways in the Regulation of Insulin Sensitivity in Men.
Acyline; Testosterone 1.62% gel; Letrozole; Placebo gel (for Testosterone 1.62% gel); Placebo pill (for Letrozole)

Type 2 Diabetes Clinical Trial using Sevelamer 1600 mg TID for 7 days; Placebo 1600 mg TID for 7 days

University Hospital, Gentofte, Copenhagen - Recruiting 35 years to 80 years.
- .
Sevelamer 1600 mg TID for 7 days; Placebo 1600 mg TID for 7 days

Nervous System, Diabetic Kidney Disease, or Diabetes Mellitus, Ty Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- Determinants of Diabetic Nephropathy in American Indians.

Diabetes Mellitus, Type 2, or Hypertension Clinical Trial using Canagliflozin; Placebo

Janssen Scientific Affairs, LLC - Recruiting 18 years to 75 years.
- A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Blood Pressure Reduction With Ambulatory Blood Pressure Monitoring (ABPM), Safety, and Tolerability of Canagliflozin in the Treatment of Subjects With Hypertension and Type 2 Diabetes Mellitus.
Canagliflozin; Placebo

Nephropathy, Retinopathy, Hypertension, Obesity, or Diabetes Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 26 years or older.
- Genetics of Type 2 Diabetes in Diverse Populations.

Type 2 Diabetes Clinical Trial using HM11260C; liraglutide

Hanmi Pharmaceutical Company Limited - Recruiting 18 years to 74 years.
- A Phase II, 12-week, Double-blind, Randomised, Parallel Group, Multi-centre, International Trial to Assess the Effect on Glycaemic Control of Five Doses of HM11260C Versus Placebo or Open-label Liraglutide in Subjects With Type 2 Diabetes.
HM11260C; liraglutide

Abnormal Glucose Tolerance, or Type 1 Diabetes Clinical Trial using CTLA4-Ig (Abatacept); Placebo

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) - Recruiting 6 years to 45 years.
- CTLA4-Ig (Abatacept)for Prevention of Abnormal Glucose Tolerance and Diabetes in Relatives At -Risk for Type 1 Diabetes.
CTLA4-Ig (Abatacept); Placebo

Type-2 Diabetes Mellitus, or Ischemic Heart Disease Clinical Trial

Thebiosignals.com - Recruiting 18 years to 80 years.
- Risk Prediction in Type II Diabetics With Ischemic Heart Disease by Cardiac Autonomic Function.

Islet Cell Transplantation, or Type 1 Diabetes Clinical Trial using Islet cell transplantation

Baylor Research Institute - Recruiting 18 years to 65 years.
- Pancreatic Islet Cell Transplantation - A Novel Approach to Improve Islet Quality and Engraftment.
Islet cell transplantation

Type 2 Diabetes Clinical Trial using Glycemic clamping

Medical College of Wisconsin - Recruiting 21 years or older.
- Adverse Effects of Systemic Hypoglycemia Exposure on Endothelial Function in Humans.
Glycemic clamping

Type 2 Diabetes Clinical Trial using Vildagliptin; Placebo

Centre d'Etudes et de Recherche pour l'Intensification du Traitement du DiabŠte - Recruiting 18 years or older.
- Evaluation of Galvus (Vildagliptin) Efficacy Versus Placebo in Patients With Type 2 Diabetes, Inadequately Controlled by Metformin and Basal Insulin, This One Having Been Properly Titrated..
Vildagliptin; Placebo

Diabetes Mellitus Clinical Trial using Luyxumia versus Lantus

Profil Institut fr Stoffwechselforschung GmbH - Recruiting 18 years or older.
- A Bicentric Open-label, Randomized, Two-parallel-group Study Investigating the Impact of Combined Lantus Insulin Glargine) and Lyxumia(Lixisenatide) on Insulin Secretion and Gastric Emptying in Subjects With Type 2 Diabetes Mellitus Not Adequately Controlled on Diet and Oral Antidiabetic Medication.
Luyxumia versus Lantus

Side Effects of Calcineurin Inhibitors, Renal Toxicity, Hepatic F Clinical Trial using Liver biopsy

Thomas Jefferson University - Recruiting 18 years or older.
- Sirolimus Switching From Calcinurin Inhibitors (CNI) 90 - 180 Days After Liver Transplantation.
Liver biopsy

Diabetes Mellitus, Type 2 Clinical Trial using Modified paleolithic diet and exercise under observation; Modified paleolithic diet and general advice on exercise

Ume† University - Recruiting 30 years to 65 years.
- Diet and Exercise in Type 2 Diabetes - a Randomized Controlled Trial.
Modified paleolithic diet and exercise under observation; Modified paleolithic diet and general advice on exercise

Type 2 Diabetes, Obesity, or Diabesity Clinical Trial using Liraglutide; Duodenal-jejunal bypass liner - Endobarrier device

Sandwell & West Birmingham Hospitals NHS Trust - Recruiting 18 years or older.
- Randomisation to Endoluminal Intestinal Liner Alone Versus With Incretin Analogue in SustainEd Diabesity (REVISE-Diabesity).
Liraglutide; Duodenal-jejunal bypass liner - Endobarrier device

Type 1 Diabetes Clinical Trial using Sensor

Medtronic Diabetes - Recruiting 2 years to 18 years.
- A Performance Evaluation of the EnliteT and Enlite 2 Glucose Sensor to Support a Full 144 Hours (6 Days) of Use in Children.
Sensor

Coronary Artery Disease, or Diabetes Mellitus Type 2 Clinical Trial using Glucagon-Like-Peptide-1/Regadenoson/Perflutren Lipid Microsphere

Mayo Clinic - Recruiting 40 years to 60 years.
- Effects of Hyperglycemia on Myocardial Perfusion in Humans With and Without Type 2 Diabetes: Modulation by Glucagon-Like-Peptide-1.
Glucagon-Like-Peptide-1/Regadenoson/Perflutren Lipid Microsphere

Diabetes Mellitus Type 1 Clinical Trial using Glucometer GM-205

GlucoVista - Recruiting 18 years to 65 years.
- .
Glucometer GM-205

Chronic Kidney Disease, or Type 2 Diabetes Mellitus Clinical Trial using AZD1722; Placebo

Ardelyx - Recruiting 18 years to 80 years.
- An Exploratory Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Design Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of AZD1722 in CKD Patients With Type 2 Diabetes Mellitus and Albuminuria.
AZD1722; Placebo

Type 1 Diabetes Mellitus Clinical Trial using Blood draw

City of Hope Medical Center - Recruiting 18 years or older.
- Detection of Human Beta Cell Death in T1DM by Methylation Specific PCR.
Blood draw

Type 1 Diabetes Clinical Trial using Algorithm ON

Stanford University - Recruiting 8 years to 25 years.
- .
Algorithm ON

Diabetes, or Diabetes Mellitus, Type 2 Clinical Trial using semaglutide; sitagliptin; placebo

Novo Nordisk - Recruiting 18 years or older.
- Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin and/or TZD in Subjects With Type 2 Diabetes (SUSTAINT 2 - vs. DPP-4 Inhibitor).
semaglutide; sitagliptin; placebo

Type 2 Diabetes Clinical Trial using Optimum Lifestyle Intervention; Standard Care

Washington University School of Medicine - Recruiting 30 years to 64 years.
- Diet and Exercise Intervention in Type 2 Diabetes.
Optimum Lifestyle Intervention; Standard Care

Type 1 and 2 Diabetes Clinical Trial using prise de sang; magnetic resonance imaging and magnetic resonance spectroscopy

Centre Hospitalier Universitaire Dijon - Recruiting 18 years or older.
- Genetic Polymorphisms, Hepatic Steatosis and Lipid Anomalies in Diabetic Patients.
prise de sang; magnetic resonance imaging and magnetic resonance spectroscopy

Type 2 Diabetes Mellitus Clinical Trial using lixisenatide AVE0010; biguanide; TZD; alpha-GI; glinide

Sanofi - Recruiting 20 years or older.
- An Open-Label, Multicenter 52-Week Study Assessing the Safety and Tolerability of Lixisenatide in Combination With Oral Anti-Diabetic Treatment in Patients With Type 2 Diabetes.
lixisenatide AVE0010; biguanide; TZD; alpha-GI; glinide

Islet Transplantation in Diabetes Mellitus Type 1, Clinical Trial using Reparixin; Placebo

Domp‚ s.p.a. - Recruiting 18 years to 70 years.
- A Phase 3, Multicenter, Randomized, Double-blind, Parallel Assignment Study to Assess the Efficacy and Safety of Reparixin in Pancreatic Islet Transplantation.
Reparixin; Placebo

Type 1 Diabetes Clinical Trial using Metformin; Placebo

T1D Exchange Clinic Network Coordinating Center - Recruiting 12 years to 19 years.
- Metformin Therapy for Overweight Adolescents With Type 1 Diabetes (T1D)--Insulin Clamp Ancillary Study for Assessment of Insulin Resistance.
Metformin; Placebo

Diabetes Mellitus, Type 2 Clinical Trial

Ohio State University - Recruiting 40 years to 60 years.
- Leukocyte Dysfunction in Diabetic Patients..

Type 2 Diabetes Clinical Trial using fotonovela

University of California, San Francisco - Recruiting 18 years or older.
- Utility of a Diabetes Themed Fotonovela to Encourage Glycemic Control: a Culturally Appropriate Tool for Education in Latinos.
fotonovela

Diabetes, or Diabetes Mellitus, Type 1 Clinical Trial using insulin aspart (faster acting insulin aspart); insulin aspart

Novo Nordisk - Recruiting 18 years to 64 years.
- A Trial Investigating the Pharmacodynamic Response of FIAsp in Subjects With Type 1 Diabetes.
insulin aspart (faster acting insulin aspart); insulin aspart

Heart Failure Clinical Trial using BAY94-8862; Placebo; Inspra (eplerenone)

Bayer - Recruiting 18 years or older.
- A Randomized, Double-blind, Double-dummy, Multi-center Study to Assess Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Emergency Presentation at the Hospital Because of Worsening Chronic Heart Failure With Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone Versus Eplerenone.
BAY94-8862; Placebo; Inspra (eplerenone)

Diabetes Mellitus, Type 2 Clinical Trial using INSULIN GLARGINE (HOE901); INSULIN GLULISINE (HMR1964)

Sanofi - Recruiting 21 years or older.
- A Comparative Study to Evaluate the Prandial Treatment Adjustment Effect Via Continuous Glucose Monitoring on Type 2 DM Patients Uncontrolled With a Basal Insulin or Premix Once a Day.
INSULIN GLARGINE (HOE901); INSULIN GLULISINE (HMR1964)

Type 2 Diabetes Mellitus Clinical Trial using Dulaglutide; Glimepiride; Placebo

Eli Lilly and Company - Recruiting 18 years or older.
- The Efficacy and Safety of Once-Weekly, Subcutaneous Dulaglutide Monotherapy Compared to Glimepiride in Patients With Type 2 Diabetes Mellitus.
Dulaglutide; Glimepiride; Placebo

Overweight, Obesity, Type 2 Diabetes Mellitus Clinical Trial using AZP-531

Aliz‚ Pharma - Recruiting 18 years to 50 years.
- A Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZP-531 in Healthy Volunteers, Overweight/Obese Volunteers and Patients With Type 2 Diabetes Mellitus.
AZP-531

Type 2 Diabetes Mellitus Clinical Trial using Insulin Lispro Mix25; Insulin Lispro Mix50

Eli Lilly and Company - Recruiting 18 years or older.
- Comparison Between Low Mixed Insulin and Mid Mixed Insulin AS Starter Insulin For Patients With TYpe 2 Diabetes Mellitus (CLASSIFY Study).
Insulin Lispro Mix25; Insulin Lispro Mix50

Diabetes Mellitus, Type I, Diabetes Mellitus, Insulin-Dependent, Clinical Trial using Imatinib Mesylate; Placebo (For imatinib mesylate)

University of California, San Francisco - Recruiting 18 years to 45 years.
- Safety and Efficacy of Imatinib for Preserving Beta-Cell Function in New-Onset Type 1 Diabetes Mellitus.
Imatinib Mesylate; Placebo (For imatinib mesylate)

Type 1 Diabetes Mellitus Clinical Trial

UMC Utrecht - Recruiting 18 years or older.
- Ovarian Ageing in Type 1 Diabetes Mellitus: the Role of Vascular Factors.

Type 2 Diabetes Mellitus Clinical Trial using LY3053102; Exenatide extended release; Placebo

Eli Lilly and Company - Recruiting 21 years or older.
- Safety, Tolerability, Pharmacokinetics, and Efficacy of LY3053102 With 12 Weeks of Treatment in Patients With Type 2 Diabetes Mellitus.
LY3053102; Exenatide extended release; Placebo

Type 2 Diabetes Mellitus Clinical Trial using LY2605541; Insulin Glargine

Eli Lilly and Company - Recruiting 20 years or older.
- A Phase 3, Open Label, Randomized, Parallel, 26 Week Treatment Study Comparing LY2605541 With Insulin Glargine as Basal Insulin Treatment in Combination With Oral Anti Hyperglycemia Medications in Asian Insulin Na‹ve Patients With Type 2 Diabetes Mellitus.
LY2605541; Insulin Glargine

Type-2 Diabetes Mellitus, or Coronary Artery Disease Clinical Trial using Ticagrelor + Aspirin; Clopidogrel + Aspirin

Mount Sinai School of Medicine - Recruiting 18 years to 75 years.
- Comparative Study of the Antithrombotic Effects of Ticagrelor and Clopidogrel in Type 2 Diabetic Patients.
Ticagrelor + Aspirin; Clopidogrel + Aspirin

Type 2 Diabetes Clinical Trial using High intensity interval training

German Diabetes Center - Recruiting 30 years to 65 years.
- Effect of High-intensity Low-volume Training on Insulin Sensitivity in Patients With Type 2 Diabetes and Healthy Lean Subjects.
High intensity interval training

Type 2 Diabetes Mellitus, or Iron Deficiency Clinical Trial using ferric carboxymaltose; NaCl (0,9%)

GWT-TUD GmbH - Recruiting 18 years or older.
- Intravenous Ferric Carboxymaltose for Improvement of Metabolic Parameters and Vascular Function in T2DM-patients With Iron Deficiency.
ferric carboxymaltose; NaCl (0,9%)

Type 2 Diabetes, or Comparative Effectiveness of Glycemia-lowerin Clinical Trial using Sulfonylurea (glimepiride); DPP-4 inhibitor (sitagliptin); GLP-1 receptor agonist (liraglutide); Insulin (glargine)

GRADE Study Group - Recruiting 30 years or older.
- Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study.
Sulfonylurea (glimepiride); DPP-4 inhibitor (sitagliptin); GLP-1 receptor agonist (liraglutide); Insulin (glargine)

Diabetes Mellitus, or Type 2 Diabetes Clinical Trial using Sitagliptin; Metformin; Placebo to sitagliptin; Placebo to metformin

Merck Sharp & Dohme Corp. - Recruiting 10 years to 17 years.
- A Phase III, Multicenter, Double-Blind, Randomized, Placebo and Metformin-Controlled Clinical Trial to Evaluate the Safety and Efficacy of Sitagliptin in Pediatric Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control.
Sitagliptin; Metformin; Placebo to sitagliptin; Placebo to metformin

Type 2 Diabetes Mellitus Clinical Trial using MK-3012; Matching placebo to MK-3012; Glimepiride; Matching placebo to glimepiride; Insulin glargine; Metformin

Merck Sharp & Dohme Corp. - Recruiting 18 years or older.
- A Multicenter, Randomized, Double-Blind Study to Evaluate the Safety, Tolerability, and Efficacy of the Addition of MK-3102 to Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Therapy.
MK-3012; Matching placebo to MK-3012; Glimepiride; Matching placebo to glimepiride; Insulin glargine; Metformin

Chronic Liver Disease, Hazardous Alcohol Use, Type 2 Diabetes, or Clinical Trial using Fibrosis Biomarkers

University of Nottingham - Recruiting 18 years or older.
- The Stratification of Liver Disease in the Community Using Fibrosis Biomarkers.
Fibrosis Biomarkers

Type 2 Diabetes Mellitus Clinical Trial using Low Glycemic Index (LGI) intervention arm; Standard Diet Intervention

National University Hospital, Singapore - Recruiting 45 years to 64 years.
- Nutrition Studies and Dietary Intervention in Individuals With Type 2 Diabetes Mellitus of Chinese, Malay and Indian Ethnicity.
Low Glycemic Index (LGI) intervention arm; Standard Diet Intervention

Type 1 Diabetes Mellitus Clinical Trial using LY2605541; Insulin Glargine

Eli Lilly and Company - Recruiting 18 years to 60 years.
- Evaluation of the Effects of LY2605541 on Respiratory Quotient During Sleep and Response to Hyperinsulinemia Compared With That of Insulin Glargine in Patients With Type 1 Diabetes Mellitus.
LY2605541; Insulin Glargine

Type 2 Diabetes, or Cardiovascular Disease Clinical Trial using Sitagliptin; Glimepiride; Placebo

University of Colorado, Denver - Recruiting 22 years to 70 years.
- Impact of Sitagliptin on Cardiovascular Exercise Performance in Type 2 Diabetes.
Sitagliptin; Glimepiride; Placebo

Type 2 Diabetes Clinical Trial

AstraZeneca - Recruiting N/A or older.
- Specific Clinical Experience Investigation for Long-term Use of Bydureon Subcutaneous Injection 2 mg.

Diabetes, or Diabetes Mellitus, Type 1 Clinical Trial using insulin aspart (FIAsp); insulin aspart

Novo Nordisk - Recruiting 6 years to 64 years.
- A Trial Investigating the Pharmacokinetic Properties of FIAsp in Children, Adolescents and Adults With Type 1 Diabetes.
insulin aspart (FIAsp); insulin aspart

Type 1 Diabetes Clinical Trial using ePID closed loop system; InsuPatch

Yale University - Recruiting 12 years to 40 years.
- Effect of the Insupatch on Automated Closed-loop Glucose Control in Type 1 Diabetes.
ePID closed loop system; InsuPatch

Type 2 Diabetes Clinical Trial

AstraZeneca - Recruiting N/A or older.
- Specific Clinical Experience Investigation for Long-term Use of Exenatide (Byetta Subcutaneous Injection).

Diabetic Foot Ulcers Clinical Trial using Gentamicin Topical Gel; Ciprofloxacin; Doxycycline

Royer Biomedical, Inc. - Recruiting 18 years or older.
- A Phase I/II, Open Label, Controlled Study to Evaluate the Safety and Efficacy of AppliGel-G [Gentamicin Sulfate Topical Gel] for Treatment of Mild to Moderately Infected Diabetic Foot Ulcers in Patients With Type 1 and Type 2 Diabetes.
Gentamicin Topical Gel; Ciprofloxacin; Doxycycline

Diabetic Nephropathy Clinical Trial using PF-04634817; Placebo

Pfizer - Recruiting 18 years or older.
- A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Center Study To Evaluate The Efficacy And Safety Of Once-Daily Administration Of A Chemokine CCR2/5 Receptor Antagonist (PF-04634817) In Adults With Type 2 Diabetes And Overt Nephropathy.
PF-04634817; Placebo

Type 2 Diabetes Clinical Trial using Lifestyle counseling with smartphone; Lifestyle counseling

York University - Recruiting 18 years to 75 years.
- Electronically Connected Health Coaching in Improving Type 2 Diabetes Self Management - Phase III Trial.
Lifestyle counseling with smartphone; Lifestyle counseling

Diabetic Nephropathy Clinical Trial using colchicine 0.5mg/d; placebo 0.5mg/d

Chongqing Medical University - Recruiting 30 years to 70 years.
- Low-dose Colchicine Intervention in Patients With Type 2 Diabetes Mellitus and Microalbuminuria: Chongqing Study.
colchicine 0.5mg/d; placebo 0.5mg/d

Diabetes, or Diabetes Mellitus, Type 2 Clinical Trial using liraglutide; metformin; sulfonylurea

Novo Nordisk - Recruiting 18 years or older.
- Efficacy and Safety of Liraglutide Versus Sulphonylurea Both in Combination With Metformin During Ramadan in Subjects With Type 2 Diabetes.
liraglutide; metformin; sulfonylurea

Diabetes, Diabetes Mellitus, Type 2, or Healthy Clinical Trial using semaglutide

Novo Nordisk - Recruiting 18 years to 85 years.
- Investigation of Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects With Various Degrees of Impaired Renal Function Compared to Subjects With Normal Renal Function.
semaglutide

Type 2 Diabetes, or Oxidative Stress Clinical Trial using ascorbic acid (Vitamin C)

University of Kansas - Recruiting 30 years to 55 years.
- Quantitative in Vivo Biomarkers of Oxidative Stress in Diabetes.
ascorbic acid (Vitamin C)

Diabetes Mellitus, Type 1 Clinical Trial using Intranasal Glucagon; Glucagon

T1D Exchange Clinic Network Coordinating Center - Recruiting 4 years to 16 years.
- Assessment of Intranasal Glucagon in Children and Adolescents With Type 1 Diabetes.
Intranasal Glucagon; Glucagon

Type 2 Diabetes Mellitus Clinical Trial using LAF237 50 mg; Placebo

Novartis - Recruiting 20 years to 74 years.
- A 12-week, Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of Equa (Vildagliptin) 50 mg Bid as an add-on Therapy to Insulin, With or Without Metformin, in Patients With Type 2 Diabetes Mellitus.
LAF237 50 mg; Placebo

Emotional Distress, Type 2 Diabetes, or Stress Clinical Trial using Mindfulness Based Stress Reduction

University of North Carolina, Chapel Hill - Recruiting 30 years or older.
- Mindfulness: a Novel Approach for the Management of Diabetes-related Distress.
Mindfulness Based Stress Reduction

Diabetes, or Diabetes Mellitus, Type 2 Clinical Trial using insulin aspart (FIAsp); basal insulin

Novo Nordisk - Recruiting 18 years or older.
- Efficacy and Safety of FIAsp in a Basal-bolus Regimen Versus Basal Insulin Therapy, Both in Combination With Metformin in Adult Subjects With Type 2 Diabetes.
insulin aspart (FIAsp); basal insulin

Diabetes Mellitus, Type 1, or Diabetes Mellitus, Type 2 Clinical Trial using Intranasal Glucagon; Glucagon

T1D Exchange Clinic Network Coordinating Center - Recruiting 18 years to 64 years.
- Efficacy and Safety of Intranasal Glucagon for Treatment of Insulin Induced Hypoglycemia in Adults With Diabetes.
Intranasal Glucagon; Glucagon

Type 2 Diabetes Mellitus Clinical Trial using Ursodiol

Mayo Clinic - Recruiting 18 years to 70 years.
- Effect of Delayed-Release Ursodeoxycholic Acid on Insulin Sensitivity, Gastric Emptying and Body Weight in Overweight or Obese Patients With Type 2 Diabetes on Metformin Treatment.
Ursodiol

Diabetes Mellitus, Type 2 Clinical Trial using PL2200 Aspirin Capsules; Enteric-coated aspirin caplets

PLx Pharma - Recruiting 21 years to 79 years.
- Reliable Inhibition of Thrombocyte Activity: Comparison of PL2200 Aspirin Capsules, 325 mg and Enteric-Coated Aspirin (RITE Study).
PL2200 Aspirin Capsules; Enteric-coated aspirin caplets

Diabetes Mellitus, Type 2 Clinical Trial using Placebo - Capsule; LY3108743 - Capsule; Placebo - Solution; LY3108743 - Solution

Eli Lilly and Company - Recruiting 21 years to 65 years.
- Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Oral Doses of LY3108743 in Healthy Subjects and Patients With Type 2 Diabetes Mellitus.
Placebo - Capsule; LY3108743 - Capsule; Placebo - Solution; LY3108743 - Solution

Diabetes, Type I, Diabetes, Type II, Angina, or Coronary Artery D Clinical Trial using Ranolazine; Placebo Pill

Brigham and Women's Hospital - Recruiting 18 years to 90 years.
- Effects of Ranolazine on Coronary Flow Reserve in Symptomatic Patients With Diabetes and Suspected or Known Coronary Artery Disease.
Ranolazine; Placebo Pill

Type 2 Diabetes Mellitus (T2DM) Clinical Trial using PE0139 Injection; Placebo

PhaseBio Pharmaceuticals Inc. - Recruiting 18 years to 65 years.
- Phase 1 Multicenter, Randomized, Double-Blind, Placebo Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Response of PE0139 Injection in Adult Subjects With Type 2 Diabetes Mellitus.
PE0139 Injection; Placebo

Diabetes Mellitus Type 1 Clinical Trial using BioChaperone insulin lispro; Humalogr

Adocia - Recruiting 18 years to 64 years.
- A Double-blinded, Randomised, Two -Period Crossover Euglycemic Clamp Trial Investigating the Pharmacokinetics, Glucodynamics and Safety of BioChaperone Insulin Lispro and Insulin Lispro (Humalogr) in Subjects With Type 1 Diabetes.
BioChaperone insulin lispro; Humalogr

Overweight, or Diabetes Mellitus Type 2 in Obese Clinical Trial using P11187; Placebo

Piramal Enterprises Limited - Recruiting 18 years to 70 years.
- A Phase I, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Safety, Tolerability, Pharmacokinetics, Food Effect and Pharmacodynamics of Single and Multiple Ascending Doses of P11187.
P11187; Placebo

Type 2 Diabetes Clinical Trial using High intensity aerobic interval training; Continuous moderate intensity exercise

University of Florida - Recruiting 30 years to 79 years.
- Mechanisms of Cardiovascular Dysfunction and Effect of Aerobic Exercise Training in Adults With Type 2 Diabetes.
High intensity aerobic interval training; Continuous moderate intensity exercise

Type 2 Diabetes Mellitus With Diabetic Nephropathy Clinical Trial using GKT137831; Placebo

Genkyotex Innovation SAS - Recruiting 18 years to 80 years.
- A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Study Evaluating the Safety and Efficacy of Oral GKT137831 in Patients With Type 2 Diabetes and Albuminuria.
GKT137831; Placebo

Type 2 Diabetes Clinical Trial using CMR

Wuhan General Hospital of Guangzhou Military Command - Recruiting 30 years to 65 years.
- Impact of Cardiac Magnetic Resonance Imaging on Endothelial Function in Type 2 Diabetes.
CMR

Diabetes Mellitus, Type 2 Clinical Trial using INSULIN GLARGINE; Metformin; DPP-4 inhibitor; Sulphonylurea

Sanofi - Recruiting 20 years or older.
- Efficacy and Safety of TrEating Type 2 Diabetic Patients With Inadequate Response to Metformin and DPP-4 Inhibitors by Adding Basal Insulin Therapy (Insulin Glargine).
INSULIN GLARGINE; Metformin; DPP-4 inhibitor; Sulphonylurea

Type 2 Diabetes or Obesity Without Diabetes Clinical Trial using Measure the threshold of detection for linoleic acid; Oral stimulation tests; Venous blood samples; Samples for genetic studies (ancillary study)

Centre Hospitalier Universitaire Dijon - Recruiting 18 years or older.
- Search for Biological Markers of Orosensory Perception of Fatty Acids in Healthy Subjects and Possible Modifications in Patients With Type 2 Diabetes and in Obese Non-diabetic Patients..
Measure the threshold of detection for linoleic acid; Oral stimulation tests; Venous blood samples; Samples for genetic studies (ancillary study)

Diabetic Nephropathy Clinical Trial using Atrasentan; Placebo

AbbVie - Recruiting 18 years to 85 years.
- A Randomized, Multicountry, Multicenter, Double-Blind, Parallel, Placebo-Controlled Study of the Effects of Atrasentan on Renal Outcomes in Subjects With Type 2 Diabetes and Nephropathy SONAR: Study Of Diabetic Nephropathy With Atrasentan.
Atrasentan; Placebo

Type 2 Diabetes Clinical Trial using LEHEL multi-nutrients supplement

Shaoguan University - Recruiting 25 years to 75 years.
- Metabolic Control Before and After Supplementation With LEHEL in Patients With Type 2 Diabetes.
LEHEL multi-nutrients supplement

Diabetes, Diabetes Mellitus, Type 2, or Healthy Clinical Trial using semaglutide; placebo; metformin; warfarin

Novo Nordisk - Recruiting 18 years to 55 years.
- An Open-label, One-sequence Cross Over, Single Centre Trial, Investigating the Influence of Semaglutide on Pharmacokinetics and Pharmacodynamics of Warfarin and Pharmacokinetics of Metformin in Healthy Subjects.
semaglutide; placebo; metformin; warfarin

Diabetes, or Diabetes Mellitus, Type 2 Clinical Trial using insulin degludec/liraglutide; insulin glargine

Novo Nordisk - Recruiting 18 years or older.
- A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide Versus Insulin Glargine in Subjects With Type 2 Diabetes Mellitus (DUALTM V - Basal Insulin Switch).
insulin degludec/liraglutide; insulin glargine

Type 2 Diabetes, or Hypogonadism Clinical Trial using Testosterone

Tameside Hospital NHS Foundation Trust - Recruiting 50 years to 80 years.
- Phase IV: Effect of Testosterone on Endothelial Function and Microcirculation in Type 2 Diabetic Patients With Hypogonadism.
Testosterone

Type 2 Diabetes Clinical Trial using Vitamin D3 Supplementation

National Institutes of Health Clinical Center (CC) - Recruiting 30 years or older.
- Vitamin D and Type 2 Diabetes (Phoenix Site).
Vitamin D3 Supplementation

Diabetes Mellitus, Type 2 Clinical Trial using glimepiride; glargine and metformin

Chongqing Medical University - Recruiting 35 years to 70 years.
- Efficacy/Safety Study of Adding Glimepiride to Type 2 Diabetes Patients With Inadequate Glycemic Control Based on Combination With Metformin And Basal Insulin.
glimepiride; glargine and metformin

Diabetes Mellitus, Insulin-Dependent, or Type 1 Clinical Trial using Oshadi Icp

Oshadi Drug Administration - Recruiting 21 years or older.
- A Single Center, Multiple-dose, Non-randomized, Dose Adjustment, Open-Label Study to Evaluate the Efficacy, Pharmacodynamics, Safety, and Tolerability of Oshadi Icp in Patients With Type 1 Diabetes Mellitus -A Phase II Clinical Study.
Oshadi Icp

Type 1 Diabetes Clinical Trial using Metformin; Placebo

University of Colorado, Denver - Recruiting 12 years to 19 years.
- Effects of Metformin on Cardiovascular Function in Adolescents With Type 1 Diabetes.
Metformin; Placebo

Type 2 Diabetes, Coronary Artery Disease, or Left Ventricular Mas Clinical Trial using alpha-lipoic acid

Wuhan General Hospital of Guangzhou Military Command - Recruiting 40 years to 70 years.
- Alpha-lipoic Acid Reduces Left Ventricular Mass in Normotensive Type 2 Diabetic Patients With Coronary Artery Disease.
alpha-lipoic acid

Diabetes, Diabetes Mellitus, Type 2, or Healthy Clinical Trial using semaglutide

Novo Nordisk - Recruiting 18 years to 85 years.
- Investigation of Pharmacokinetics, Safety and Tolerability of Oral Semaglutide (NNC0113-0217) in Subjects With Mild, Moderate and Severe Degrees of Hepatic Impairment Compared to Subjects With Normal Hepatic Function.
semaglutide

Metabolic Diseases, Type 2 Diabetes, Cardiovascular Disease Clinical Trial using Carnosine

Slovak Academy of Sciences - Recruiting 25 years to 50 years.
- Randomised Placebo Controlled Study of the Effect of Carnosine Diabetes and Cardiovascular Risk Factors.
Carnosine

Type 2 Diabetes, or Hypertension Clinical Trial using Individual treatment

Odense University Hospital - Recruiting 18 years or older.
- Individually Tailored Treatment of Type 2 Diabetes.
Individual treatment

Type 1 Diabetes Clinical Trial

University Medical Centre Ljubljana - Recruiting N/A to 7 years.
- The Influence of Diabetes Related Technology, Education and Psychological Support on Metabolic Control in Young Children With Type 1 Diabetes.

Diabetes Clinical Trial using Lifestyle Intervention

University of Massachusetts, Amherst - Recruiting 18 years to 45 years.
- Estudio PARTO: Proyecto pAra Reducir Diabetes Tipo dOs / Project Aiming to Reduce Type twO Diabetes.
Lifestyle Intervention

Diabetes Mellitus Clinical Trial using Microprobe glucose sensor

Imperial College London - Recruiting 18 years to 75 years.
- Clinical Assessment of a Novel Microprobe Array Continuous Glucose Monitor for Type 1 Diabetes.
Microprobe glucose sensor

Diabetes Mellitus Clinical Trial using MK-8521; Liraglutide; Placebo

Merck Sharp & Dohme Corp. - Recruiting 18 years to 69 years.
- A Phase Ib, Multicenter, Placebo and Active- Comparator-Controlled, Randomized, Double-Blind, Clinical Trial to Evaluate the Safety and Efficacy of MK-8521 Compared to Placebo and a Diabetes Drug in Subjects With Type 2 Diabetes Mellitus.
MK-8521; Liraglutide; Placebo

Type 1 Diabetes Clinical Trial using Carbohydrate-rich meal; Exercise

Institut de Recherches Cliniques de Montreal - Recruiting 12 years or older.
- An Open-label, Randomized, Three-way, Multicenter Study to Compare the Efficacy of Single-hormone Closed-loop Strategy, Dual-hormone Closed-loop Strategy and Conventional Insulin Pump Therapy in Regulating Overnight Glucose Levels at Home in Adolescents and Adults With Type 1 Diabetes.
Carbohydrate-rich meal; Exercise

Diabetes Mellitus, Type 2, or Healthy Volunteers Clinical Trial using Dulaglutide; Placebo

Eli Lilly and Company - Recruiting 18 years to 75 years.
- Pharmacokinetics of a Single Dulaglutide Dose in Healthy Chinese Subjects and of Multiple Dulaglutide Doses in Chinese Patients With T2DM.
Dulaglutide; Placebo

Sub-optimal Vitamin D Status, Pre-diabetes, or Insulin Resistance Clinical Trial using Vitamin D3 supplementation

Queen's University, Belfast - Recruiting 18 years or older.
- Effect of Vitamin D3 Supplementation on Insulin Resistance and Cardiovascular Risk Factors in People at High Risk of Type 2 Diabetes and Cardiovascular Disease (The DIR Study).
Vitamin D3 supplementation

Type 2 Diabetes Clinical Trial using Vitamin D; Placebo

University of Florida - Recruiting 30 years to 65 years.
- Effects of Treating Vitamin D Deficiency in Poorly Controlled Type 2 Diabetes.
Vitamin D; Placebo

Type 1 Diabetes, or Type 2 Diabetes Clinical Trial using Medtronic MiniMed 620G or 640G Insulin Pump

Medtronic Diabetes - Recruiting 7 years or older.
- A User Evaluation of the MiniMedr 620G and 640G Insulin Pumps and Guardianr Link Transmitter.
Medtronic MiniMed 620G or 640G Insulin Pump

Type 1 Diabetes, or Eating Disorder Clinical Trial

Park Nicollet Institute - Recruiting 12 years or older.
- Development of an Instrument to Screen for Eating Disorder Symptoms in Persons With Type 1 Diabetes.

Diabetes, or Diabetes Mellitus, Type 1 Clinical Trial using BioChaperoner Combo; Humalogr Mix25

Adocia - Recruiting 18 years to 64 years.
- Phase 1 Study to Assess the Efficacy and Safety of BioChaperoner Combo and Humalogr Mix 25 in Subjects With Type 1 Diabetes.
BioChaperoner Combo; Humalogr Mix25

Diabetic Neuropathy, or Cognitive Impairment Clinical Trial using Tocotrienol; Placebo

University of Science Malaysia - Recruiting 20 years or older.
- A Clinical Study on the Neuroprotection by Tocotrienols in Type 1 and Type 2 Diabetes Mellitus.
Tocotrienol; Placebo

Type 2 Diabetes Clinical Trial using Red Grape Cells (RGC); Placebo (for Red Grape Cells (RGC))

Tel Aviv University - Recruiting 30 years to 70 years.
- Effects of Red Grape Cells (RGC) Powder on Glycemic and Lipid Control in Patients With Type 2 Diabetes ª A Double-blind, Randomized, Placebo Controlled Study.
Red Grape Cells (RGC); Placebo (for Red Grape Cells (RGC))

Type 2 Diabetes Clinical Trial using Sitagliptin + glargine; Basal Bolus; Metformin and sitagliptin; Metformin and sitagliptin + glargine 50%; Metformin and sitagliptin + glargine 80%

Emory University - Recruiting 18 years to 80 years.
- Randomized Controlled Trial on the Safety and Efficacy of Sitagliptin Therapy for the Inpatient Management of General Medicine and Surgery Patients With Type 2 Diabetes.
Sitagliptin + glargine; Basal Bolus; Metformin and sitagliptin; Metformin and sitagliptin + glargine 50%; Metformin and sitagliptin + glargine 80%

Diabetes, or Diabetes Mellitus, Type 2 Clinical Trial using liraglutide; lixisenatide

Novo Nordisk - Recruiting 18 years or older.
- Efficacy and Safety of Liraglutide Versus Lixisenatide as add-on to Metformin in Subjects With Type 2 Diabetes.
liraglutide; lixisenatide

Diabetes Mellitus Type 2, or Obesity Clinical Trial using Behavioural change programme

Norwegian University of Science and Technology - Recruiting 18 years to 65 years.
- The VEND RISK-study. Preventing Diabetes Type 2 in Overweight Persons in the V‘rnes Region, Central-Norway..
Behavioural change programme

Type 2 Diabetes Mellitus, or Cardiovascular Disease Clinical Trial using Saxagliptin

Duke University - Recruiting 45 years to 75 years.
- Mechanistic Assessment of the Properties of Saxagliptin in Subjects Undergoing Coronary Artery Bypass Graft Surgery: a Randomized, Double-Blind, Placebo-Controlled Clinical Trial.
Saxagliptin

Excessive Weight Gain in Pregnancy as Antepartum Condition, Obesi Clinical Trial using Exercise and Nutrition Intervention

McMaster University - Recruiting 18 years or older.
- Be Healthy in Pregnancy (B-HIP): A Randomized Clinical Trial (RCT) to Study Nutrition and Exercise Approaches for Healthy Pregnancy.
Exercise and Nutrition Intervention

Type 2 Diabetes Clinical Trial using Dapagliflozin; Placebo matching with Dapagliflozin; Saxagliptin; Metformin immediate release (IR)

Bristol-Myers Squibb - Recruiting 18 years or older.
- A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Therapy With Dapagliflozin Added to Saxagliptin in Combination With Metformin Compared to Therapy With Placebo Added to Saxagliptin in Combination With Metformin in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin and Saxagliptin.
Dapagliflozin; Placebo matching with Dapagliflozin; Saxagliptin; Metformin immediate release (IR)

Type 2 Diabetes Mellitus, or Nephropathy Clinical Trial using Valsartan; Placebo; Probucol

Guangdong General Hospital - Recruiting 30 years to 70 years.
- A Prospective Randomized, Controlled, Open-labeled Trial of Probucol Combined With Valsartan in Patients With Diabetes Nephropathy.
Valsartan; Placebo; Probucol

Celiac Disease, or Diabetes Mellitus, Type 1 Clinical Trial using Gluten Free Diet

The Hospital for Sick Children - Recruiting 8 years to 35 years.
- A Randomized Controlled Trial to Evaluate the Efficacy and Safety of a Gluten-Free Diet in Patients With Asymptomatic Celiac Disease and Type 1 Diabetes, Celiac Disease and Diabetes - Dietary Intervention and Evaluation Trial (CD-DIET).
Gluten Free Diet

Diabetes Mellitus Type 1, or Retinal Branch Vein Occlusion Clinical Trial using COX inhibitor; L-NG-monomethyl arginine citrate; COX inhibitor + L-NG-monomethyl arginine citrate

University of Aarhus - Recruiting 20 years to 55 years.
- Diameter Changes of Retinal Vessels During Hypoxia.
COX inhibitor; L-NG-monomethyl arginine citrate; COX inhibitor + L-NG-monomethyl arginine citrate

Type 1 Diabetes Clinical Trial using ferumoxytol

Massachusetts General Hospital - Recruiting 18 years or older.
- Ferumoxytol Enhanced Magnetic Resonance Imaging of Type 1 Diabetes Progression.
ferumoxytol

Type 2 Diabetes Clinical Trial using ITCA 650 60 mcg/day; sitagliptin

Intarcia Therapeutics - Recruiting 18 years to 80 years.
- A Phase 3, Randomized, Active Comparator, Double-Blind, Multi-Center Study to Compare the Efficacy, Safety and Tolerability of ITCA 650 to Sitagliptin as Add-on Therapy to Metformin in Patients With Type 2 Diabetes.
ITCA 650 60 mcg/day; sitagliptin

Type 2 Diabetes Clinical Trial using ITCA 650 (exenatide in DUROS)

Intarcia Therapeutics - Recruiting 18 years to 80 years.
- An Open-Label Multi-Center Sub-Study to Evaluate the Efficacy, Safety and Tolerability of ITCA 650 in Patients With Type 2 Diabetes With High Baseline HbA1c.
ITCA 650 (exenatide in DUROS)

Diabetes, Type I Clinical Trial using continuous glucose sensors and insulin pump

Rabin Medical Center - Recruiting 10 years to 65 years.
- Closing the Loop Between Glucose Sensor and Insulin Pump-developing an Algorithm.
continuous glucose sensors and insulin pump

Type 1 Diabetes Clinical Trial using Accu-Chek Combo System

Rabin Medical Center - Recruiting 6 Months to 6 years.
- Evaluation of the Use of the Accu-Chek Combo System in Young Patients With Type 1 Diabetes.
Accu-Chek Combo System

Diabetes Mellitus Type 2 in Obese, or Obesity Clinical Trial

Mayo Clinic - Recruiting 21 years to 55 years.
- Epigenetics and the Origin of Muscle Insulin Resistance in Humans.

Type 2 Diabetes, or Oxidative Stress Clinical Trial using N-acetylcysteine

Utzschneider, Kristina, M.D. - Recruiting 18 years to 75 years.
- Effect of Anti-oxidants on Beta-cell Function in Humans.
N-acetylcysteine

Type 1 Diabetes Clinical Trial using Dose D1 of interleukin-2; placebo; Dose D2 of Interleukin-2; Dose D3 of interleukin-2

Assistance Publique - H“pitaux de Paris - Recruiting 7 years to 12 years.
- Induction of Regulatory T Cells for the Treatment of Recently Diagnosed Type 1 Diabetes: Dose Finding Study of the Lowest Active Dose of IL-2 in Children.
Dose D1 of interleukin-2; placebo; Dose D2 of Interleukin-2; Dose D3 of interleukin-2

Type 2 Diabetes Clinical Trial using Exenatide; Humulin-N

Taipei Veterans General Hospital, Taiwan - Recruiting 30 years to 70 years.
- The Effects of Short-Term Exenatide Therapy on the Beta-Cell Function and Long-term Glycemic Control in Newly Diagnosed Type 2 Diabetic Patients.
Exenatide; Humulin-N

Type 2 Diabetes Clinical Trial using Mirtoselect

University of Aberdeen - Recruiting 40 years to 70 years.
- Study of Acute Oral Administration of Anthocyanins on Insulin Resistance.
Mirtoselect

Chronic Obstructive Pulmonary Disease, or Type 2 Diabetes Clinical Trial using Tool; Self-management Support Program

Maastricht University Medical Center - Recruiting 40 years to 70 years.
- RCT It's LiFe! to Evaluate the Effectiveness of the Monitoring and Feedback Tool and the Corresponding Counseling Protocol (Self-management Support Program) to be Executed by Practice Nurses in Primary Care.
Tool; Self-management Support Program

Type 2 Diabetes Clinical Trial using Metformin

University of Southern Denmark - Recruiting 18 years to 40 years.
- The Relation Between Heritability and the Trough Concentration of Metformin in Plasma Under Steady-state in Twins.
Metformin

Type 1 Diabetes Clinical Trial using Exenatide

Yale University - Recruiting 18 years to 56 years.
- A Pilot Study to Determine the Effects of a Single Dose of Exenatide (Byetta r) on the Acute Metabolic Responses to a Mixed Meal or Intravenous Glucose Tolerance Test in Patients With Type 1 Diabetes.
Exenatide

Type 1 Diabetes Clinical Trial using ePID closed loop system; liraglutide

Yale University - Recruiting 18 years to 40 years.
- Effect of Liraglutide on Automated Closed-loop Glucose Control in Type 1 Diabetes.
ePID closed loop system; liraglutide

Diabetes, or Hypothyroidism Clinical Trial using Euthyrox (levothyroxine)

Maastricht University Medical Center - Recruiting 40 years to 65 years.
- Effects of Thyroid Hormone Treatment on Mitochondrial Function, Ectopic Fat Accumulation, Insulin Sensitivity and Brown Adipose Tissue in Type 2 Diabetes Mellitus.
Euthyrox (levothyroxine)

Critical Lower Limb Ischemia, or Type-2 Diabetes Mellitus Clinical Trial using Group A: Intramuscular; Group B: Intraarterial; Group C: Intravenous; Group D: Surgical endovascular treatment with maximum medicamentous treatment

University Hospital Ostrava - Recruiting 18 years or older.
- Randomised Clinical Study of Safety and Efficacy of Autologous Bone Marrow Aspirate Concentrate (BMAC) for No-option_critical Limb Ischemia in Type-II Diabetes Mellitus Patients. (DIALEG).
Group A: Intramuscular; Group B: Intraarterial; Group C: Intravenous; Group D: Surgical endovascular treatment with maximum medicamentous treatment

Type 2 Diabetes Clinical Trial using Exercise

Rigshospitalet, Denmark - Recruiting 30 years to 70 years.
- .
Exercise

Type 1 Diabetes Mellitus Clinical Trial using iBOLUSED

University of Virginia - Recruiting 21 years to 65 years.
- Evaluation of a Simulation-Based Educational Tool for Personalized Feedback in Insulin Therapy Management.
iBOLUSED

Type 2 Diabetes Clinical Trial using MP513; Placebo

Handok Pharmaceuticals Co., Ltd. - Recruiting 18 years or older.
- Phase III, Double Blind, Parallel-group, Randomized, Placebo Controlled Study to Compare the Efficacy and Safety of MP-513 When Added to Ongoing Metformin Monotherapy In Patients With Type 2 DM.
MP513; Placebo

Type 2 Diabetes, or Acute Coronary Event Clinical Trial using Home visits; Consultation by telephone

UMC Utrecht - Recruiting N/A or older.
- Tailored Support for Type 2 Diabetes Patients With an Acute Coronary Event After Discharge From Hospital.
Home visits; Consultation by telephone

Diabetes Mellitus Type II Clinical Trial using NONE intervention

Ziv Hospital - Recruiting 35 years or older.
- Predictors of Future Type 2 Diabetes Mellitus in Circassians Minority in Israel.
NONE intervention

Type II Diabetes Mellitus, or Obesity Clinical Trial using PolyGlycopleXr - PGXr; Rice Flour (placebo)

InovoBiologic Inc. - Recruiting 18 years to 75 years.
- A Randomized, Double Blind, Placebo Controlled Trial Evaluating the Effects of a Highly Viscous Non-starch Polysaccharide (PolyGlycopleXr - PGXr), on Glycemic Control, Cardiometabolic Risk Factors and Weight Loss in Overweight and Obese Type II Diabetics Enrolled in a Medically Supervised Weight Management Program..
PolyGlycopleXr - PGXr; Rice Flour (placebo)

Type 2 Diabetes, or Hypertension Clinical Trial using Step count prescription; Usual care

McGill University Health Center - Recruiting 18 years to 95 years.
- Step Monitoring to Improve ARTERial Health.
Step count prescription; Usual care

Type 2 Diabetes Clinical Trial using 18F-AV-133; 10% Arginine Hydrochloride-R-Gene 10

Avid Radiopharmaceuticals - Recruiting 30 years to 65 years.
- Quantitative PET Imaging of Pancreatic Beta-Cell Mass in Healthy Overweight/Obese Subjects, Subjects With Prediabetes, and Type 2 Diabetes Patients With 18F-FP-DTBZ (18F-AV-133).
18F-AV-133; 10% Arginine Hydrochloride-R-Gene 10

Diabetes, or Cardiovascular Disease Clinical Trial using Uncontrolled nutritional intervention with a supplemental beverage; Placebo

Laval University - Recruiting 40 years to 65 years.
- Beneficial Effects of a Polyphenol Enriched Beverage on Type 2 Diabetes Prevention and on Cardiovascular Risk Profil of Men and Women With Insulino Resistance..
Uncontrolled nutritional intervention with a supplemental beverage; Placebo

Diabetes, or Type 1 Diabetes Clinical Trial using Alpha 1-Antitrypsin (AAT, Aralast NP)

University of Colorado, Denver - Recruiting 6 years to 45 years.
- The Effects of Open Label Alpha-1 Antitrypsin on the Progression of Type 1 Diabetes in Subjects With Detectable C-peptide.
Alpha 1-Antitrypsin (AAT, Aralast NP)

Type 2 Diabetes Clinical Trial using Glipizide; Acarbose

Shanghai Jiao Tong University School of Medicine - Recruiting 40 years to 60 years.
- An Open-label, Randomized , Phase 4 Study to Compare the Different Efficacies of à-glucosidase Inhibitor and Sulfonylurea on Improvement of Intestinal Microbiome and Serum Incretins in Patients With Type 2 Diabetes.
Glipizide; Acarbose

Type 2 Diabetes Clinical Trial using glyburide; GlucoNorm

University of British Columbia - Recruiting 65 years or older.
- Effect of GlucoNorm vs Glyburide on Post-Prandial Hyperglycemia in Elderly Subjects With Type 2 Diabetes.
glyburide; GlucoNorm

Type 1 Diabetes Mellitus Clinical Trial using Insulin pump therapy (CSII) plus continuous glucose monitoring (CGM); Multiple daily insulin injections (MDI)

Steno Diabetes Center - Recruiting 18 years to 75 years.
- The Effect of Sensor-Augmented Continuous Subcutaneous Insulin Infusion Compared to Multiple Daily Insulin Injections in Prevention of Increasing Urinary Albumin Excretion Rate in Type 1 Diabetes Mellitus.
Insulin pump therapy (CSII) plus continuous glucose monitoring (CGM); Multiple daily insulin injections (MDI)

Diabetes Mellitus, or Diabetic Retinopathy Clinical Trial using Insulin pump; Multiple daily insulin injections; Bariatric surgery; Medical therapy for type 2 diabetes

Glostrup University Hospital, Copenhagen - Recruiting 18 years or older.
- Retinal Adaptation to Intensified Insulin Therapy and Bariatric Surgery in Patients With Diabetes.
Insulin pump; Multiple daily insulin injections; Bariatric surgery; Medical therapy for type 2 diabetes

Type 2 Diabetes, or Renal Insufficiency Clinical Trial using Glargine & glulisine

Loyola University - Recruiting 18 years or older.
- Glargine Dosing in Hospitalized Patients With Type 2 Diabetes and Renal Insufficiency.
Glargine & glulisine

Type 2 Diabetes Clinical Trial using Insulin; Metformin; Sitagliptin

Taipei Veterans General Hospital, Taiwan - Recruiting 30 years to 80 years.
- á-Cell Function and Glycemic Control of Basal Insulin, Metformin or Sitagliptin in Newly Diagnosed Type 2 Diabetic Patients With Moderate Hyperglycemia.
Insulin; Metformin; Sitagliptin

Diabetes Mellitus, Type 2, Metabolic Syndrome X, or Mild Cognitiv Clinical Trial

Maastricht University Medical Center - Recruiting 40 years to 75 years.
- Functional MRI Biomarkers of Cognitive Decrements in Diabetes.

Type 2 Diabetes Clinical Trial using diet intervention

German Diabetes Center - Recruiting 18 years to 69 years.
- Short Term Diet Intervention in Newly Diagnosed Type 2 Diabetes. a Randomised, Multicentric, Controlled, Clinical Trial.
diet intervention

Type 2 Diabetes Clinical Trial using Cholecalciferol

Florida International University - Recruiting 30 years to 70 years.
- The Effect of Vitamin D Supplementation on Cardiovascular Risk Factors Among Hispanics and African Americans With Type 2 Diabetes.
Cholecalciferol

Vitamin D Deficiency, Type 2 Diabetes Mellitus, or Cardiovascular Clinical Trial using Vitamin D3; Calcium carbonate

Washington University School of Medicine - Recruiting 50 years to 70 years.
- Vitamin D and Early Markers of Cardiovascular Disease in African Americans.
Vitamin D3; Calcium carbonate

Obesity, Morbid, Diabetes Mellitus, Type 2, or Gastric Bypass Clinical Trial

CPL Associates - Recruiting 18 years to 95 years.
- Comparison Of Endotoxin Concentration And Intestinal Microbiologic Flora Before And After Roux-En-Y Gastric Bypass Or Gastric Banding Surgery In Morbidly Obese Patients With Type 2 Diabetes Mellitus.

Type 2 Diabetes, Coronary Artery Disease, Hypertension, or Dyslip Clinical Trial using intensive control; standard control

Kyoto University, Graduate School of Medicine - Recruiting 20 years or older.
- Intensive Blood Pressure and LDL Lowering for Better Survival and Cardiovascular Outcome in Diabetic Patients With Coronary Artery Disease: Randomized Controlled Trial.
intensive control; standard control

Type I Diabetes Clinical Trial using Sernova Cell Pouch

University of Alberta - Recruiting 18 years to 68 years.
- A Phase I/II Study of the Safety and Efficacy of Sernova's Cell PouchTM for Therapeutic Islet Transplantation.
Sernova Cell Pouch

Type 2 Diabetes Clinical Trial using placebo; exenatide

Amylin Pharmaceuticals, LLC. - Recruiting 10 years to 17 years.
- Safety and Efficacy of Exenatide as Monotherapy and Adjunctive Therapy to Oral Antidiabetic Agents in Adolescents With Type 2 Diabetes.
placebo; exenatide

Type 2 Diabetes, or Gastric Banding Clinical Trial using Liraglutide; Orlistat; Liraglutide + Orlistat

East Carolina University - Recruiting 25 years to 70 years.
- LIRAGLUTIDE AND ORLISTAT TREATMENT FOR PERSISTENT TYPE 2 DIABETES AFTER GASTRIC BANDING: A PILOT STUDY.
Liraglutide; Orlistat; Liraglutide + Orlistat

Type 2 Diabetes Mellitus, or Hypercholesterolemia Clinical Trial using Atorvastatin; Placebo

University of Roma La Sapienza - Recruiting 18 years to 75 years.
- Effects on Oxidative Stress, Coagulation, Platelet Activation and Inflammatory Indexes of Atorvastatin and/or Aspirin Treatment in Patients at High Risk of Vascular Events.
Atorvastatin; Placebo

Type 1 Diabetes Mellitus Clinical Trial using Lisofylline

Eastern Virginia Medical School - Recruiting 18 years to 45 years.
- A Safety, Tolerability and Bioavailability Study of Lisofylline After Continuous Subcutaneous (12 mg/kg) and Intravenous (9 mg/kg) Administration in Subjects With Type 1 Diabetes Mellitus.
Lisofylline

Type 1 Diabetes Clinical Trial using Pro insulin peptide; Saline

Cardiff University - Recruiting 18 years to 40 years.
- Phase 1b Study of Proinsulin (PI) Peptide Immunotherapy in New-Onset Type 1 Diabetes.
Pro insulin peptide; Saline

Type 1 Diabetes Clinical Trial

Uppsala University Hospital - Recruiting 18 years or older.
- Open Study to Investigate Pancreatic Islet Mass by Positron Emission Tomography Using the Tracer [11C]5-hydroxytryptophane.

Type 2 Diabetes Mellitus Clinical Trial

Universita di Verona - Recruiting 18 years to 75 years.
- The Verona Newly Diagnosed Type 2 Diabetes Study. Construction of a Biobank of Diabetes Related Genotypes and Phenotypes.

Type 2 Diabetes, or Peripheral Vascular Disease Clinical Trial using Subjects with diabetes who plan to undergo elective infrainguinal bypass surgery will receive standard diabetes care by their admitting physician; Subjects with diabetes who plan to undergo elective infrainguinal bypass surgery will receive diabetes care under the direction of the Diabetes Action Team; Subjects without diabetes will have their blood glucose levels monitored while in the hospital

University of British Columbia - Recruiting 30 years or older.
- Early Post-Operative Dysglycemia in Patients With and Without Diabetes Post-Infrainguinal Bypass Surgery and the Effectiveness of a Diabetes Action Team in the Management of Diabetes Post Infrainguinal Bypass Surgery on Glycemic Control, Length of Stay, and Infection Rates: A Pilot Study.
Subjects with diabetes who plan to undergo elective infrainguinal bypass surgery will receive standard diabetes care by their admitting physician; Subjects with diabetes who plan to undergo elective infrainguinal bypass surgery will receive diabetes care under the direction of the Diabetes Action Team; Subjects without diabetes will have their blood glucose levels monitored while in the hospital

Cardiovascular, Diabetes, Orthostatic Hypotension, or Type 2 Diab Clinical Trial using Home-based walking program (Aerobic Exercise)

University of British Columbia - Recruiting 65 years or older.
- The Use of a Home-based Walking Program to Treat Orthostatic Hypotension in Older Adults With Type 2 Diabetes.
Home-based walking program (Aerobic Exercise)

Blood Pressure Clinical Trial using DASH diet plus exercise; ADA diet

Hospital de Clinicas de Porto Alegre - Recruiting 30 years to 90 years.
- Lifestyle Changes in Patients With Type 2 DM and Hypertension: DASH Diet and Exercise Effects.
DASH diet plus exercise; ADA diet

Type 2 Diabetes Mellitus Clinical Trial using Pistachios; control diet

Institut Investigacio Sanitaria Pere Virgili - Recruiting 25 years to 65 years.
- Effect of Pistachio Intake on Insulin Resistance and Type 2 Diabetes Mellitus.
Pistachios; control diet

Type 1 Diabetes Clinical Trial

University of Minnesota - Clinical and Translational Science Institute - Recruiting 18 years to 65 years.
- Measurement of Glucose/Glycogen Metabolism in Humans Using Magnetic Resonance at 4 or 7 Tesla.

At-risk Drinking, or Type 2 Diabetes Clinical Trial using Brief alcohol intervention; General health education

Rhode Island Hospital - Recruiting 18 years or older.
- Brief Alcohol Intervention to Reduce At-Risk Drinking Among Type 2 Diabetics.
Brief alcohol intervention; General health education

Type 2 Diabetes Mellitus, or Weight Gain Clinical Trial using Sensewear Bodymedia armband

Radboud University - Recruiting 18 years to 85 years.
- Determinants of Insulin-induced Weight Gain in Type 2 Diabetes Mellitus.
Sensewear Bodymedia armband

Type 1 Diabetes Clinical Trial using Family-based cognitive-behavioral treatment

Children's Hospital Medical Center, Cincinnati - Recruiting 13 years to 17 years.
- Supporting Treatment Adherence Needs in Diabetes: The STAND Study.
Family-based cognitive-behavioral treatment

Obesity and Type 2 Diabetes Clinical Trial using Circuit Training; Circuit training + motivational interviewing; Control

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) - Recruiting 14 years to 18 years.
- Circuit Training and Motivational Interviewing to Reduce Type 2 Diabetes in Youth.
Circuit Training; Circuit training + motivational interviewing; Control

Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, or Metaboli Clinical Trial

University of California, Irvine - Recruiting 40 years to 65 years.
- Mitochondria and Metabolic Syndrome in a Southern California Chinese Cohort.

Pregnancy Complications Clinical Trial using Metformin; Insulin (NPH and Regular)

The University of Texas Health Science Center, Houston - Recruiting 18 years to 52 years.
- A Randomized, Controlled Trial of Metformin Versus Insulin in Women With Type 2 Diabetes Mellitus During Pregnancy in a Population With Severe Health Disparities.
Metformin; Insulin (NPH and Regular)

Peripheral Artery Tonometry, Diabetes, Children, or Obesity Clinical Trial

Universitaire Ziekenhuizen Leuven - Recruiting 12 years to 19 years.
- Peripheral Artery Tonometry in Children With Type 1 Diabetes and Obese Children..

Type 1 Diabetes Mellitus Clinical Trial using IN-105; Insulin Lispro Injection

Biocon Limited - Recruiting 18 years to 45 years.
- An OpenLabel, Multicenter, Non-randomized, ActiveControlled, SingleDose Escalation, Study to Evaluate the Pharmacodynamics,Pharmacokinetics,Safety, and Tolerability of IN-105 Under Fed Conditions In Patients With Type 1 Diabetes Mellitus.
IN-105; Insulin Lispro Injection

Type 2 Diabetes Clinical Trial using Gliclazide MR and Insulin Glargine Injection; Biosynthetic Human Insulin Injection

Servier (Tianjin) Pharmaceutical Co. LTD. - Recruiting 35 years to 65 years.
- Phase 4 Study of Comparison of Combination Therapy of Gliclazide MR and Basal Insulin With Pre-mix Insulin Monotherapy for the Patients With Type 2 Diabetes Mellitus.
Gliclazide MR and Insulin Glargine Injection; Biosynthetic Human Insulin Injection

Type 2 Diabetes Clinical Trial using Januvia

University Hospital, Gentofte, Copenhagen - Recruiting 18 years to 80 years.
- Phase 3, Double Blinded, Placebo Controlled Study of the Effects of 12 Weeks DPP-IV Inhibitor Treatment on Secretion and Action of the Incretin Hormones in Patients With Type 2 Diabetes.
Januvia

Type 2 Diabetes, or Morbid Obesity Clinical Trial

University Hospital, Gasthuisberg - Recruiting 18 years to 70 years.
- Mechanisms of Type 2 Diabetes Improvement, Besides Weightloss After Gastric Bypass.

Diabetes Mellitis Type 2 Clinical Trial using DA-1229; Placebo

Dong-A Pharmaceutical Co., Ltd. - Recruiting 20 years to 45 years.
- A Dose Block-randomized, Double-blind, Placebo-controlled, Single/Multiple Dosing, Dose Escalation Clinical Phase 1 Study to Investigate the Safety, Tolerance, and Pharmacokinetics/Pharmacodynamics of DA-1229 in Healthy Male Subjects.
DA-1229; Placebo

Diabetes Mellitus, Type 2, or Heart Failure, Diastolic Clinical Trial using Exenatide

National Heart, Lung, and Blood Institute (NHLBI) - Recruiting 30 years or older.
- Treatment With Glucagon-Like Peptide-1 Receptor, Exenatide, in Patients With Diabetes and Heart Failure With Normal Left Ventricular Ejection Fraction.
Exenatide

Type 2 Diabetes Mellitus, or Obesity Clinical Trial using Insulatard; Detemir

University of Surrey - Recruiting 18 years or older.
- A 24-Week, National, Single-Centre, Open-Labelled, Randomised, Parallel-Group Trial Comparing Energy Expenditure With Insulin Detemir Versus NPH Insulin Using a Basal-Bolus Regimen With Insulin Aspart as the Mealtime Insulin in Subjects With Type 2 Diabetes.
Insulatard; Detemir

Type 2 Diabetes Mellitus, or Obesity Clinical Trial using Oral glucose tolerance test (OGTT), isoglycemic iv. clamp, liquid meal test, gastric emptying rate

Glostrup University Hospital, Copenhagen - Recruiting 18 years or older.
- Incretin Physiology and Beta-Cell Function Before and After Remission of Type 2 Diabetes - Effects of Long-Term Weight Loss Following Laparoscopic Adjustable Gastric Banding.
Oral glucose tolerance test (OGTT), isoglycemic iv. clamp, liquid meal test, gastric emptying rate

Diabetes Mellitus, Type 2 Clinical Trial using Rosiglitazone; dietary recommendation for weight maintenance

Stanford University - Recruiting 20 years to 75 years.
- Rosiglitazone-Induced Weight Gain.
Rosiglitazone; dietary recommendation for weight maintenance

Type 2 Diabetes, or Obesity Clinical Trial using laparoscopic gastric banding

Garvan Institute of Medical Research - Recruiting 18 years to 70 years.
- The Role of Adipocyte-Derived Inflammatory Cytokines in the Pathogenesis of Diabetes, Dyslipidaemia, Atherosclerosis and Gastro-Oesophageal Reflux Disease: the Effects of Medical and Surgical Weight Loss.
laparoscopic gastric banding

Type 2 Diabetes Mellitus, or Hypertension Clinical Trial using Intensive therapy Valsartan,Fluvastatin

Kitasato University - Recruiting 20 years or older.
- Intensive Medical Treatment for Nephropathy Caused by Type 2 Diabetes With Hypertension.
Intensive therapy Valsartan,Fluvastatin

Diabetes Mellitus, Type 2 Clinical Trial using Benfotiamine; Placebo

Ruhr University of Bochum - Recruiting 35 years to 70 years.
- Effects of a Chronical Treatment With Benfotiamine in People With Type 2 Diabetes Mellitus on Pre- and Postprandial Endothelial Function, as Well as on the Function of the Autonomic Nervous System.
Benfotiamine; Placebo

Diabetes, Hypertension, or Dyslipidemia Clinical Trial using MEDIC

Providence VA Medical Center - Recruiting 18 years to 85 years.
- Multi-Targeted Cardiac Risk Intervention in Type 2 Diabetes.
MEDIC

Diabetes Mellitus Type 2 Clinical Trial

Assaf-Harofeh Medical Center - Recruiting 40 years to 90 years.
- Angiotensin Converting Enzyme Inhibitors & Angiotensin Receptor Blocker in the Treatment of Type 2 Diabetic Patients Adverse Drug Effects and Drug Interactions- a Survey in an Internal Medicine Department..

Healthy, Type 2 Diabetes, or Endotoxemia Clinical Trial using Escherichia Coli Endotoxin

Rigshospitalet, Denmark - Recruiting 25 years to 80 years.
- Renal Plasma Flow During Experimental Human Endotoxemia.
Escherichia Coli Endotoxin

Diabetes Mellitus, Type 2 Clinical Trial using dual-action insulin analog

Jikei University School of Medicine - Recruiting 20 years to 80 years.
- .
dual-action insulin analog